Apolipoprotein E elicits isoform-dependent effects on macrophage cytokine secretion. by Tsoi, Lo Ming. & Chinese University of Hong Kong Graduate School. Division of Biochemistry.
Apolipoprotein E Elicits Isoform-dependent 
Effects on Macrophage Cytokine Secretion 
TSOI Lo Ming 
: A Thesis Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Biochemistry 
• The Chinese University of Hong Kong 
September 2006 
The Chinese University of Hong Kong holds the copyright of this thesis. Any 
person(s) intending to use a part or whole of the materials in the thesis in a 
proposed publication must seek copyright release from the Dean of the 
Graduate School. 
/ y 學 大 ^ ^ ttiifSI 
I declare that the thesis here submitted is original except for source material 
explicitly acknowledged. I also acknowledge that I am aware of University policy 
and regulations on honesty in academic work, and of the disciplinary guidelines and 
procedures applicable to breaches of such policy and regulations, as contained in the 
website http://www.cuhk.edu.hk/policy/academichonesty/ 
兔 减 • 15/9/2006 
Signature Date 
Tsoi Lo Ming s04074600 
Name Student ID 
Apolipoprotein E Elicits Isoform-dependent Effects on Macrophage Cytokine 
Secretion 
Thesis Title 
Thesis/ Assessment Committee 
Professor Kwok-Nam Leung (Chair) 
Professor Yuan-Yuan Ho (Thesis Supervisor) 
Professor Zhen-Yu Chen (Committee Member) 
Professor Richard Deckelbaum (External Examiner) 
(I) ACKNOWLEDGEMENTS 
I would like to express my gratitude to my supervisor, Prof. Y.Y. Ho, for her patience, 
support, and encouragement throughout my postgraduate studies. She has inspired 
me valuable insights on the workings of academic research. 
Special thanks also go to the members of MMW 509, especially Ms. Teresa Tsang, 
Ms. Peggy Law, Ms. Ivy Geng, Ms. Kin-yee Wong, Ms. Priscilla Chan, Mr. Eric 
Chan and Ms. Vicky Wong for their valuable suggestions and support. 
Last, but not least, I would like to thank Mr. Chok-yan Au Yeung and my family 
members for their understanding and love during the past two years. Their support 
and encouragement was essential for the completion of this dissertation. 
This thesis project was supported by the Funding from the Research Grants Council 




There is increasing evidence showing that atherosclerosis is intrinsically an 
inflammatory process. Macrophage, the most prominent cell type in atherosclerotic 
lesions, contributes to the process by secreting numerous pro-inflammatory cytokines 
and accumulating lipoprotein to form foam cells. Cytokines secreted by macrophage 
are important for extracellular matrix production and smooth muscle cell (SMC) 
proliferation and migration, which promote atherosclerosis. Foam cells are abundant 
source of apolipoprotein E (apoE)，a polymorphic protein with three common 
isoforms, apoE2, apoE3 and apoE4. Many studies have suggested that apoE elicits 
anti-atherogenic functions in ar isoform-dependent manner, but its role on 
inflammation is still unclear. In this study, we aim to investigate the effects of apoE 
isoforms on cytokine secretion in macrophages, and explore the underlying signaling 
mechanisms. Since the circulating levels of tumor necrosis factor-alpha (TNF-a) and 
interluekin-6 (IL-6) show strong correlation with the risk of atherosclerosis, these 
two cytokines are the focus of my study. Using mouse peritoneal macrophage cell 
line J774A.1 without endogenous apoE expression as a model, apoE2-, apoE3- and 
apoE4- stable expressing polyclonal cell lines have been established. Results showed 
that when compared with apoE3-expressing cells, apoE2- and apoE4-expressing cells 
had significantly higher (p<0.05) LPS-activated secretion of tumor necrosis 
factor-alpha (TNF-a) and interleukin-6 (IL-6), and this effect is 
serum/lipoprotein-independent. Interestingly, relative to apoE3-expressing cells, the 
expression of phosphorylated ERKl/2 and p38 MAPK, kinases known to regulate 
cytokine production, was also significantly higher (p<0.05) in apoE2- and 
apoE4-expressing cells upon LPS activation. Application of MEKl/2 inhibitor 
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partially abolished the isoform-dependent effects of endogenous apoE on cytokine 
secretion (p<0.05), indicating that ERKl/2 MAPKs play important roles in mediating 
such effects. Taken together, endogenous apoE elicits an isoform-dependent effect on 
macrophage cytokine secretion, with apoE3 being the most potent isoform in 
suppressing cytokine secretion. The downregulation of ERKl/2 is responsible for the 
most potent anti-inflammatory effects in apoE3-expressing cells. 
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Chapter 1 ： Introduction 
1.1. ApoHpoprotein and Lij oprotein Metabolism 
Plasma lipids, including triglycerides, phospholipids and cholesterol, have • 
relative low solubility in the blood stream and require special transport 
vehicles called lipoproteins as carriers. Lipoproteins are categorized into 
four main classes according to their size and density: chylomicrons, very 
low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and 
high-density lipoproteins (HDL). Structurally, they consist of hydrophobic 
lipid cores surrounded by a surface monolayer of amphipathic lipids and 
specific proteins called apolipoproteins. In addition to their role in 
providing structural integrity of lipoproteins, apolipoproteins also 
function as allosteric cofactors of various lipid-metabolizing enzymes and 
ligands for receptor-mediated lipid transport (Mahley and Innerarity, 
1984). The target protein of the present study is apolipoprotein E (apoE), 
which plays a key role in lipid metabolism and protects against 
atherosclerosis. Table 1.1 shows the properties of different classes of 
lipoproteins. 
Table 1.1: Properties of Lipoproteins (Drew, 2000). 
Demity Major Lipoprotein Class Origin Major Lipid Carrier (g/ml) Apolipoproteins 
Dietary triglycerides Chylomicrons < 0.95 Intestine A, B-48, C, E 
and cholesterol 
Hepatic triglycerides 
VLDL 0.95 - 1 . 0 0 6 Liver B-lOO, C, E and cholesterol 
LDL 1 .019-1 .063 Liver B-lOO Cholesterol 
Liver, Cholesterol, 
HDL 1.063 - 1 . 2 1 0 A, C, E Intestine phospholipids 
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1.2. Molecular Information of ApoE 
The human APOE gene is located at chromosome 19ql3.2 and is closely 
linked to the APOC-I/C-II pseudogene complex. It consists of four exons 
and three introns, with a length of approximate 3.7 kbps (Eichner et ai, 
2002). The promoter s哪ence TATAATT is located at about 30 bps 
upstream from the transcriptional initiation site. Transcription of the 
APOE gene produces an apoE mRNA comprising 1163 nucleotides, 
which is then translated into a 317-amino acid pre-apoE, with an 
18-amino acid N-terminal signal peptide that is removed after being 
transported to the endoplasmic reticulum (ER). The mature apoE protein 
is then transferred to the Golgi apparatus where it will undergo 0-linked 
glycosylation at threonine-194 prior to secretion (Greenow et ai, 2005). 
The secreted apoE is a 299-amino acid peptide with a molecular mass of 
approximate 34 kDa (Mahley and Rail, 2000). Although most apoE is 
secreted from the hepatic cells as the glycosylated form, glycosylation is 
not essential for the synthesis or the secretion of the protein (Zanni et ai, 
1989). The functional relevance of this modification remains unclear 
currently. 
1.3. Tissue Distribution of ApoE 
The liver, which produces two-third to three-fourth of the plasma apoE, is 
the major site for apoE synthesis. The second largest site of apoE 
synthesis is the brain, which expresses apoE at about one-third of the liver 
secretion (Elshourbagy et ai, 1985). Hepatic parenchymal cells and 
astrocytes are the cell types responsible for apoE production in the liver 
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and brain, respectively. Macrophages are also important apoE producers, 
providing nearly 10% o f the plasma apoE. Other peripheral tissues such 
as the spleen, the lungs, ovary, adrenal gland, kidney and muscles also 
secrete apoE and about 20 - 40% o f the plasma apoE are derived from 
these extra-hepatic tissues (Blue et al.’ 1983). Unexpectedly, the 
epithelium o f intestine, an important tissue for l ip id transport, does not 
produce apoE. Figure 1.1 summarizes the distribution o f apoE in various 
human tissues. This widespread production o f apoE in hepatic and 
extra-hepatic tissues suggested the importance o f apoE in l ip id 
metabolism and possibly other functions unrelated to l ip id transport 
(Mahley, 1988). 
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Figure 1.1: Relative amount of apoE mRNA in different human 
tissues. (Rebhan et al” 1997) 
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1.4. Functions of ApoE 
ApoE facilitates the removal of excess circulating lipoprotein via two 
receptor-mediated pathways, namely the LDL receptor (LDLR) pathway 
and the heparan sulfate proteoglycans (HSPG)/LDLR-related protein 
(LRP) pathway. 
LDL receptor is found in both hepatic and extrahepatic cells, whose 
expression is highly regulated. Both apoB-100 and apoE are ligands for 
LDL receptor, where apoE shows a higher affinity to it. The binding of 
apoB-lOO/apoE to LDL receptor result in a rapid endocytosis of the 
lipoprotein (Mahley and Rail, 2000). The uptake of VLDL, LDL and HDL 
by hepatic and extrahepatic cells is mediated via LDL receptors (Mahley 
etai, 1984). 
LRP is a large endocytic receptor which belongs to the LDL receptor 
family. Similar to the LDL receptor, LRP is found in both hepatic and 
extrahepatic tissues, with apoE being one of its ligands. In the liver, LRP 
plays a key role in the multi-step clearance of chylomicron remnants. The 
apoE secreted by liver is first bound to the HSPG-rich surface and entraps 
chylomicron remnant in the space of Disse, where they undergo lipolytic 
processing by hepatic or lipoprotein lipases. The lipoprotein are then 
taken up by the LDL receptor, transferred from the HSPG to the LRP for 
internalization, or are taken up as part of the HSPG/LRP complex in 
hepatocytes (Cooper, 1997) (Figure 1.2). However, there is increasing 
evidence suggesting that the apoE interaction with LDL receptor or 
HSPG/LRP might lead to signal transduction events that can modulate cell 
functions unrelated to lipid transport, which create a more complicated 
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picture in regard to these pathways. 
In addition to its role is facilitating the removal of excess lipoproteins, 
apoE also play an important role in the process called reverse cholesterol 
transport, which remove excess cholesterol from peripheral cells and 
tissues (e.g. macrophages) to liver via HDL (Dory, 1991). Besides, apoE 
can stimulate the production of hepatic VLDL and triglyceride directly, so 
their levels can be adjusted by varying apoE synthesis (Kuipers et al, 
1997). Moreover, apoE can activate enzymes such as hepatic lipase, 
cholesteryl ester transfer protein and LCAT, which functions to transfer 
lipid among lipoproteins and cells (Greenow et al., 2005). 
Despite its key role in lipid transport, apoE carries other physiological 
functions that are independent of lipid metabolism and most of them are 
reported to be anti-atherogenic. For example, apoE can inhibit cell 
adhesion molecule expression on vascular endothelium (Stannard et al., 
2001), inhibit platelet aggregation (Riddell et al, 1997)，suppress T 
lymphocytes activation and proliferation (Kelly et al” 1994), inhibit 
smooth muscle cells (SMCs) proliferation (Ishigami et al., 2000) and 
migration (Zhu et al., 2003), stimulate neurite extension (Mahley and 
Huang, 1999) and act as an antioxidant (Smith et al., 1998). These 
functions are mediated through different signaling transduction pathways 
and involved in the interaction with various members of LDL receptor 
family. This part will be further discussed in section 1.9.3.2. 
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Figure 1.2: Receptor pathways involved in the clearance of 
chylomicron remnants by liver. Chylomicron remnant particles are first 
sequestered in the space of Disse, where they undergo final lipolytic 
processing by lipoprotein lipase (LPL) or hepatic lipase (HL). The 
lipoprotein is then taken up through (a) LDL receptor, (b) HSPG/LRP 
pathway, and (c) HSPG alone. In HSPG/LRP pathway, lipoproteins could 
(2a) first bind to HSPG and then transferred to LRP for uptake or (2b) 
bind to and taken up by，n HSPG/LRP complex (Mahley and Rail, 2000). 
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1.5. Genetic Polymorphism of ApoE 
Due to the presence of two single nucleotide polymorphisms (SNPs) in 
exon 4 (+3937 and +4075) of human APOE gene, three alleles (82, 83 and 
e4) arise and apoE becomes a polymorphic protein with three common 
isoform apoE2, E3 and E4 (Fig. 1.3). These apoE isoforms differ from 
one another only with a single amino acid substitution; apoE3 contains 
cysteine at 112 and arginine at 158，while apoE2 has cysteine and apoE4 
has arginine at both positions. The three apoE isoforms could be easily 
separated based on their isoelectric point through isoelectric focusing 
(Figure 1.4). Different combination of the three alleles result in three 
homozygous (apoE2/2, dpoE3/3, and apoE4/4) and three heterozygous 
(apoE2/3, apoE3/4, and apoE2/4) phenotypes. From population studies, it 
is shown that apoE3 carrier is the most frequent while apoE2 carrier is the 
rarest in the human populations (Eichner et al., 2002) (Table 1.2). 
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Figure 1.3: APOE gene on human chromosome 19. The APOE gene 
contains four exons and three introns. The polymorphic sequence was 
located at exon 4 and the corresponding nucleotide changes for amino 
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Figure 1.4: Isoelectric focusing of delipidated apoE isoforms. The 
apoE2, E3 and E4 isoforms differ sequentially by one charge unit as a 
result of the amino acid substitutions. The minor isoforms beneath each 
major apoE isoforms are the sialylated isoforms (Mahley and Rail, 2000). 
Table 1.2: Relative frequencies of APOE alleles in eleven 
populations (Eichner et ai, 2002). 
Relative Frequencies (%) Population 
82 §3 ^ 
Africans (Nigerians) 2.8 66.2 31.0 
African Americans 13.1 66.8 20.1 
American Indians 1-7 85.0 13.3 
Caucasians 
Fr—ngham, 8.3 78.5 13.1 
Massachusetts 
Munster, West Germany 8.2 78.2 13.6 
Finland 3.9 76.7 19.4 
France 8.1 80.2 11.7 
Italy 7.3 82.7 10.0 
Chinese 7.4 84.4 8.2 
Japanese 3.7 84.6 11.7 
Mexican Americans 3.9 85.9 10.2 
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1.6. Protein Structure and Characteristics of ApoE Isoforms 
The structure of apoE contains two independently folded domains that are 
linked by a protease-sensitive loop (Mahley, 1988). The amino-terminal 
domain (residues 1-191) has an ordered structure consisting of four 
amphipathic a-helix bundle (residues 24 - 42, 54 - 81，87 - 122 and 
130 - 164，respectively) arranged in an anti-parallel fashion with the 
hydrophobic side orientated towards the interior of the bundle (Wilson et 
al., 1991). A short additional helix (residues 44 - 53) connects helices 1 
and 2 (Weisgraber, 1994). This amino-terminal region contains the LDL 
receptor- and HSPG/LRP-binding sites, with a basic amino acids-rich 
(mainly arginine and lysine) segment in helix 4 (residues 136 — 150) 
(Mahley and Rail, 2000). This segment is essential for the ionic 
interaction with the acidic residues aspartate and glutamate on the LDL 
receptor and the negatively charged carboxylate and sulfate groups of 
proteoglycans, which has been demonstrated by mutagenesis and 
chemical modification (Libeu et al., 2001; Nimpf and Schneider, 2000). A 
region spanning residues 171 - 183 also contains essential elements for 
stabilization of the receptor-binding domain (Greenow et al., 2005). 
Sequence alignment with other apolipoproteins suggested that the 
carboxyl-terminal domain (residues 216-299) of apoE, which adopts an 
amphipathic a-helical conformation (i.e. contains apolar residues on one 
face and polar residues on the other), is important for its lipid-binding 
capability (Mahley and Rail, 2000). 
Although apoE2 and apoE4 differ from apoE3 only with a single amino 
acid substitution, some important changes of their protein structures are 
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observed. Studies from x-ray crystallography showed that the substitution 
of cysteine for arginine at residue 158 in apoE2 (compared with apoE3) 
destroyed the salt bridge formed between aspartic acid-154 and 
arginine-158 (observed in apoE3) and leads to a new salt bridge formation 
between arginine-150 and aspartic acid-154. The side chain of 
arginine-150 finally being pulled out of the positive ion cloud (residue 
140-150), and reduced 100-fold of its potential for LDL receptor binding 
(Dong et aL, 1996). 
The substitution of arginine for cysteine at residue 112 in apoE4 
(compared with apoE3) provided an ionic interaction with glutamic 
acid-109, which excludes the arginine-61 side chain from its usual 
position and become more exposed at the side of helix 2. This results in a 
new salt bridge formation between arginine-61 in the amino-terminal 
domain and the glutamic acicI-255 in the carboxyl-terminal domain of 
apoE. Such unique domain interaction in apoE4 changes its preference for 
binding to VLDL, as mutation of either arginine-61 or glutamic acid-255 
changes the lipoprotein preference of apoE4 from VLDL to HDL (which 
apoE2 and apoE3 show nreference binding) (Dong and Weisgraber, 1996). 
This special conformation may be responsible for several apoE4-specific 
roles in vivo. Figure 1.5 gives a comparison of the three-dimensional 




Figure 1.5: Comparison of three-dimensional structure of apoE 
isoforms. In apoE2, the' substitution of cysteine for arginine at residue 
158 destroyed the salt bridge formed between aspartic acid-154 and 
arginine-158, leading to a new salt bridge formation between arginine-150 
and aspartic acid-154. In apoE4, the substitution of arginine for cysteine 
at residue 112 providei an ionic interaction with glutamic acid-109, 
which excludes the arginine-61 side chain from its usual position and 
become more exposed at the side of helix 2 (Mahley and Rail, 2000). 
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1.7. Plasma and Cellular Expression Level of ApoE Isoforms 
The plasma level of apoE varies among isoforms, ApoE2 is associated 
with an increased level of apoE ( -5 mg/dL) compared to apoE3 (-2.2 
mg/dL), while apoE4 is associated with a reduced level of apoE ( � 1 . 8 
mg/dL) (Mahley and Rail, 2000) (Figure 1.6). The high level of plasma 
apoE2 is possibly linked to its defective binding to LDL receptor, leading 
to a high level of circulating VLDL and low clearance of apoE2. On the 
other hand, apoE4 preferentially associates with VLDL, which increases 
receptor-mediated endocytosis and results in a more rapid catabolism than 
other apoE isoforms (Wahrle and Holtzman, 2003). The cellular 
expression of apoE also differs among isoforms. Previous studies have 
demonstrated a greater cellular accumulation of apoE2 and apoE3 than 
apoE4 in neurons, fibroblasts, and hepatocytes (Ji et ai, 1998). Moreover, 
the brain of apoE4 knock-in mice shows a significant lower expression of 
apoE than apoE3 knock-in mice (Ramaswamy and Xu et ai, 2005) 
However, the molecular mechanism underlies the low expression of 
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Figure 1.6: Effect of apoE isoforms on plasma apoE level. ApoE2 
carrier is associated with an increased level of apoE while apoE4 is 
associated with a decreased level of apoE (Mahley and Rail, 2000). 
1.8. Association Between ApoE Isoforms and Plasma Lipid Profiles 
In most populations, apoE2 carriers are associated with decreased levels 
of plasma cholesterol when compared to apoE3 carriers, whereas apoE4 
carriers show increased levels of plasma cholesterol, especially 
LDL-cholesterol (Figure 1.7). The high cholesterol level observed in 
apoE4 carriers is believed to increase their risk on developing heart 
disease (Hallman et al.’ 1991). 
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Figure 1.7: Association between apoE isoforms and plasma lipid 
profile. ApoE2 carrier is associated with a decreased level of total plasma 
cholesterol whereas apoE4 increases it. TG, total plasma triglycerides; 
VLDL-C，VLDL cholesterol; HDL-C, HDL cholesterol; LDL-C, LDL 
cholesterol; TC, total plasma cholesterol (Mahley and Rail, 2000). 
1.9. ApoE Polymorphisms and Pathophysiological Conditions 
1.9.1. Type ffl Hyperlipoproteinemia (Type HI HLP) 
Type III HLP is a hereditary dyslipidemia characterized by the 
accumulation of abnormal lipoproteins called p-VLDL，owing to their 
P-electrophoretic migration instead of the usual pre-p migration of typical 
VLDL. (3-VLDL is apoE-containing cholesterol and 
triglycerides-enriched remnants, therefore patients with type III 
hyperlipoproteinemia usually have combined hypertriglyceridemia and 
hypercholesterolemia, and are often associated with premature 
development of atherosclerosis. Nearly all patients with type III HLP are 
homozygous for apoE2, suggesting that delayed clearance of remnant 
lipoproteins is due to the LDL receptor-binding defect of apoE2 carriers 
(Waldenand Hegele, 1994). 
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1.9.2. Alzheimer's Disease 
Alzheimer's disease (AD) is a neurodegenerative disorder of the brain 
characterized by the presence of neuritic amyloid-containing senile 
plaques (SPs) and intraneuronal neurofibrillary tangles (NFTs). ApoE is 
expressed at a low level in neurons under physiological condition but is 
detected at high level in amyloid plaques and NFTs. The APOE s4 allele 
has been genetically linked to the risk and age of AD onset, with 
homozygous 84 carriers having a 50-90% chance of developing the 
disease by the age of 85 years. 
Numerous studies have explained the association of the APOE s4 allele 
with AD. ApoE4 is demonstrated to play a role in the modulation of the 
deposition and clearance of amyloid P (Ap) peptides and the formation of 
plaques. Its expression in neurons leads to impairment of the antioxidative 
defense system, disruption of cytoskeletal structure and function, altered 
phosphorylation of tau leads to the formation of neurofibrillary tangles, 
and promote endosomal abnormalities linked to Ap overproduction. 
However, the molecular mechanisms of these harmful effects mediated by 
apoE4 are still mostly unknown (Brecht et al., 2004). 
1.9.3. Atherosclerosis 
1.9.3.1. Atherosclerosis - An Inflammatory Process 
Atherosclerosis, characterized by the progressive deposition of 
lipids and fibrous elements in arteries, is the main cause of heart 
disease and stroke in developed countries. It is now clear that 
atherosclerosis is not simply a degenerative process, but rather a 
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chronic inflammatory condition (Uichi, 2003). 
A number of risk factors, such as high blood pressure, smoking, 
high blood cholesterol, diabetes, obesity or infection, increased 
the permeability of vascular endothelium to lipoproteins, 
especially LDL. In the intima, these LDLs undergo modification 
(mainly oxidation) and their accumulation induces the expression 
of specific adhesion molecules on the surface of vascular 
endothelial cells and mediates monocyte adhesion. The 
chemoattractant chemokines produced by endothelial cells then 
direct the migration of monocytes into the intima, where they 
proliferate and differentiate into macrophages. These activated 
macrophages subsequently take up modified lipoproteins through 
scavenger receptors (SR-A and CDS6) which developed during 
differentiation and secrete large quantities of apoE. Originally, 
these immune responses function to scavenge the harmful 
oxidized LDL, but in reality they are poorly degradable targets 
for macrophages and lead to the transformation of macrophage 
into lipid-laden foam cells. The excessive accumulation of free 
cholesterol eventually causes death of foam cells, contributing 
their lipid content to fatty streak formation. Intimal macrophages 
also secrete large amount of cytokines (e.g. TNF-a, IL-6) and 
fibroblast growth factors (e.g. PDGF) which stimulate the SMC 
migration and proliferation from media to intima, and also their 
production of 户-xtracelMar matrix. The fatty streaks, together 
with the accumulated SMCs and extracellular matrix, forms the 
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fibrous plaques which continually increase in size. Further 
calcification is usually observed in the advanced stage of 
atheroma progression (Lusis, 2000). 
Transition from the chronic to acute phase of atherosclerosis is 
mainly due to thrombosis, which causes the blockage of blood 
flow in arteries. Thrombus formation occurs when there is a 
physical disruption of plaque, that permits contact between blood 
and tissue factor in the lesion core. It is now clear that the 
biomechanical strength of plaque, rather than the degree of 
luminal obstruction by an atheroma, is an important determinant 
of thrombosis. Matrix-degrading enzymes produced by activated 
macrophages lower the structural components (e.g. collagen, 
elastin) in the plaque and play a key role in reducing its tensile 
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Figure 1.8: An overview of atherosclerosis. The increased 
permeability of vascular endothelium leads to diffusion of LDL 
into intima. In the intima, these LDLs undergo mainly oxidation 
and induce cell adhesion molecules on the surface of endothelial 
cells and promote monocyte adhesion. The adhered monocytes 
transmigrate into the intima, where they proliferate and 
differentiate into macrophages. These activated macrophages 
then take up oxidized LDL through scavenger receptors to form 
foam cells. Foam cells secrete large quantities of apoE, cytokines 
and fibroblast growth factors，which subsequently stimulate 
SMC migration and proliferation from media to intima. The fatty 
streaks from dead foam cells then interact with the accumulated 
SMCs and extracellular matrix to forms fibrous plaques. The 
physical disruption of plaque finally causes thrombosis and lead 
to acute clinical complications (Lusis, 2000). 
1.9.3.2. Roles of ApoE in Atherosclerosis 
ApoE knockout mice has been used extensively as the animal 
model for studying atherosclerosis since they develop 
spontaneous atherosclerosis even under a low fat diet (Jean et al” 
1999). Although apoE can enter the arterial wall from peripheral 
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sources (e.g. liver), it is believed that the large quantities of apoE 
found in atherosclerotic lesion are synthesized by local resident 
macrophages. The high expression of apoE in atherosclerotic 
lesion and the development of atherosclerosis in apoE knockout 
mice suggest this protein exerts important anti-atherogenic 
functions. How-.ver, it was later shown that the anti-atherogenic 
function of apoE is isoform-dependent, with apoE2 and apoE4 
carriers demonstrated an increased risk to the disease (Mahley 
and Rail, 2000). 
(a) Functions Associated to Lipid Metabolism 
Atherosclerosis is associated with an increased level of total 
plasma cholesterol (Davidoff, 1991). As mentioned in section 1.4, 
apoE plays an important role in maintaining a normal level of 
plasma cholesterol. However, since apoE2 is defective in LDL 
receptor binding and apoE4 shows preferential binding to VLDL, 
their carriers are associated with an increased level of LDL and 
plasma cholesterol, respectively (Mahley and Rail, 2000). 
Besides, both exogenously-added (Hayek et al., 1994) and 
endogenously-expressed (Mazzone and Reardon, 1994) apoE4 
shows the least effective in promoting reverse cholesterol 
transport (Cullen et ai, 1998). This suggests the increased risk of 
atherosclerosis in apoE2 and apoE4 carrier is related to their 
differential effects on lipid metabolism. 
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(b) Functions Independent of Lipid Metabolism 
Macrophage production of apoE in the arterial wall has been 
demonstrated to provide protection against atherosclerosis 
independently from its role in lipoprotein clearance. Studies 
using transgenic mice with apoE-deficient macrophages showed 
a ten-fold increase in the atherosclerosis development without 
any significant change in their plasma cholesterol or triglyceride 
(Fazio et ai, 1997). Similarly, the plasma cholesterol levels 
remain constant in transgenic mice expressing apoE only in the 
arterial wall, which shows an inhibition on diet-induced 
atheroma formation (Shimano et ai, 1995). Although many of 
them are still under exploration, some of these anti-atherogenic 
roles of apoE are discovered recently and will be discussed in the 
following section. 
(i) Inhibition of adhesion molecule expression on 
endotheliuiii. 
ApoE can inhibit the expression of vascular cell adhesion 
molecule-1 (VCAM-1) in human endothelial cells, which 
facilitate monocytes adhesion and initiate atherosclerosis 
(Dansky et ai, 2001). This inhibition is possibly achieved 
through the activation of the NO synthase (NOS) signaling, 
as the application of the NOS inhibitor significantly blocked 
the inhibitory effect of apoE on VCAM-1 expression. 
Moreover, the suppression of VCAM-1 is observed in all 
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three apoE isoforms, with apoE4 elicits the lowest inhibitory 
effect, regardless of endogenous expression or exogenous 
addition of apoE (Stannard et al., 2001). By suppressing the 
endothelial adhesion molecules expression, apoE reduces the 
recruitment of monocytes and inhibit lesion development. 
(ii) Inhibition of platelet aggregation 
NO is a potent inhibitor of platelet activation and aggregation. 
ApoE inhibits platelet aggregation by binding to the LDL 
receptor related protein 8 (LRP8) on platelets and their 
interaction activates the L-arginine: NO signal transduction 
pathway, which eventually enhances the production of 
platelet-derived NO (Bocksch et al., 2001). This 
anti-aggregation effect of apoE has been demonstrated by 
applying several NOS inhibitors (Riddell et al., 1997). Since 
the three apoE isoforms show a similar affinity to LRP8, they 
suppress platelet aggregation at a similar degree (Riddell et 
al., 1999). By means of inhibiting platelet aggregation, apoE 
indirectly prevents thrombosis. 
(iii)Suppression of T lymphocytes activation and 
proliferation. 
Apart from macrophages, T lymphocytes, which elicit 
adaptive immune response and secrete cytokines such as 
IFN-y to stimulate SMC growth and extracellular matrix 
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accumulation (Lusis, 2000), are also recruited to intima 
during atherosclerosis. Therefore, suppressing T lymphocyte 
activation and proliferation can limit the rate of lesion 
progression. The. activation of T lymphocytes involves 
mitogen biiiding to T cell receptor, which subsequently 
activates phospholipase C to hydroiyze phosphatidylinositol 
bisphosphate (PIP2) into diacylglycerol and inositol 
triphosphate. The second messengers diacylglycerol and 
inositol triphosphate then activate protein kinase C and 
induce intracellular calcium mobilization respectively, which 
stimulate the production of IL-2 and induce T lymphocyte 
proliferation via IL-2 receptor (Kelly et ai, 1994). Therefore, 
the pool of phosphatidylinositol bisphosphate is important in 
maintaining the T lymphocyte responses upon mitogen 
stimulation. 
ApoE suppresses T lymphocyte activation by inhibiting the 
intracellular calcium mobilization and phosphatidylinositol 
bisphosphate turnover. It also inhibits the production of 
bioactive IL-2 at post-translational level and the assembly of 
IL-2 receptor complexes, which consequently arrest T 
lymphocytes at the Gi phase of cell cycle and inhibit their 
proliferation (Bocksch et ai, 2001). Since the apoE isoform 
used in the above study was not specified, the effect of apoE 
isoforms remains unclear. Nevertheless, the high expression 
of apoE in macrophage and its suppressive effect on T 
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lymphocyte activation and proliferation strongly suggest that 
apoE has a significant immunoregulatory role in vivo. 
(iv)Inhibition of SMC proliferation and migration 
ApoE inhibits PDGF-induced vascular SMC proliferation 
through the activation of NO synthase (Ishigami et ai, 2000), 
which subsequently inhibits mitogen-activated protein kinase 
(MAPK) activation and cyclin D1 expression required for 
cell cycle progression. This results in the G() phase arrest of 
cell cycle (Ishigami et ai, 1998). The activation of NO 
synthase is triggered by the binding of apoE to HSPG on 
SMC surface (Swertfeger and Hui, 2001). Since apoE4 is less 
effective than apoE2 and apoE3 in binding to HSPG, it shows 
no significant inhibition on SMC proliferation even at high 
concentrations. ApoE2 could inhibit SMC proliferation, but a 
higher dosage of it is required to achieve a similar level of 
inhibition as imposed by apoE3. Therefore, apoE3 is the 
most potent isoform in inhibiting SMC proliferation, 
followed by apoE2, and with apoE4 being the least effective 
isoform (Hui and Basford, 2005). 
On the other hand, apoE inhibits SMC migration by 
interacting with LRP-1 on SMC surface, leading to an 
increased cAMP level and subsequent activation of 
cAMP-dependent protein kinase A (PKA) (Zhu and Hui, 
2003). Since the three apoE isoforms do not show preference 
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binding to LRP-1, they are equally effective in inhibiting 
SMC migration (Hui and Basford, 2005). Interestingly, a 
higher concentration of apoE is required to inhibit SMC 
proliferation, in comparison to the low apoE concentration 
required for inhibition of SMC migration. Nevertheless, the 
inhibition of SMC proliferation and migration by apoE can 
slow down the development of fibrous plaque, and prevent 
transferring to a more acute phase of the disease. 
(V) Antioxidant 
ApoE-knockout mice show enhanced oxidative stress and 
LDL oxidation in the atherosclerotic lesions, and their 
circulating lipoproteins are also more oxidized and 
susceptible to oxidation in vitro, suggesting the antioxidative 
role of apoE (Bocksch et ai, 2001). Such antioxidative 
property is related to the ability of apoE to bind to metal ions 
(mainly copper and iron), which are the cofactor for most 
oxidation processes. Moreover, all three apoE isoforms exert 
antioxidative activity, with apoE2 being the most and apoE4 
the least effective (Jean et ai, 1999). This is consistent with 
the finding from human studies that apoE4 carriers have a 
significant increase in serum lipid peroxide levels, which is 
not observed in apoE3/3. and apoE3/2 subjects (Smith et ai, 
1998). Since apoE can decrease lipid oxidation, it lowers the 
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formation and accumulation of oxidized LDL, i.e. inhibit 
atherogenesis. 
1.9.3.3. TNF-a and IL-6 in Atherosclerosis 
The proinflammatory cytokines TNF-a and. IL-6 are secreted by 
activated macrophages during atherogenesis. Several population 
studies have demonstrated a strong correlation between the 
circulating level of TNF-a and IL-6 and the risk of 
atherosclerosis (Haddy et al., 2003). IL-6 is an important inducer 
of the acute phase response, especially in stimulating the hepatic 
production of C-reactive protein (CRP), whose level is also 
strongly associated with an increased chance of cardiovascular 
disease (Mendall et al., 1997). Moreover, increased IL-6 level 
has been linked to an elevation of circulating fibrinogen and 
triglyceride (Mendall and Asante，1997)，cell adhesion molecules 
ICAM-1 and L-selectin expression on endothelium (Haddy et al, 
2003) and reduced HDL cholesterol in the population (Yudkin et 
al., 2000). As for animal studies, IL-6 knockout mice show a 
significant reduced recruitment of macrophages into the 
atherosclerotic lesion (Schieffer et al” 2004), while the injection 
of IL-6 leads to an increased lesion size in mice (Huber et al, 
1999). 
The atherogenic effect of TNF-a is quite similar to IL-6. In the 
population studies, an elevation in circulating TNF-a is 
associated with a higher E-selectin and ICAM-1 cell adhesion 
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molecules expression (Haddy et al., 2003), increased 
triglycerides level (Haddy et al., 2003) and decreased HDL 
cholesterol (Mendall et ai, 1997). In the animal studies, the 
disruption of TNF-a gene in mice leads to a reduction of lesion 
size, and decreases the ICAM-1, VCAM-1 and MCP-1 adhesion 
molecules exprrssion. Moreover, macrophages from TNF-a gene 
disrupted mice show a lower oxidized LDL uptake and 
expression of SR-A (Ohta et ai, 2005). These findings from 
population and animal studies suggest the importance of TNF-a 
and IL-6 in the development of atherosclerosis. 
1.10. Macrophage Cytokine Expression and MAPKs 
1.10.1. Organization of MAPKs Signaling Pathway 
The response of cells to extracellular stimuli involves a series of signal 
transduction events across the plasma membrane and through the 
cytoplasm to the nucleus. MAPKs are ubiquitous mediators of signal 
transduction, which play a key role in regulating many physiological 
functions. Each family of MAPKs consists of a set of three sequentially 
acting kinases: a MAPK, a MAPK kinase (MAPKK), and a MAPKK 
kinase (MAPKKK). In the presence of extracellular stimuli, a small 
GTP-binding protein of the Ras/Rho family is often first activated, 
leading to the phosphorylation of MAPKKK, a serine/threonine kinase. 
The MAPKKK activation subsequently phosphorylates and activates a 
MAPKK, which then increases MAPK activity through the dual 
phosphorylation on the threonine and tyrosine residues located in the 
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activation loop. Once activated, MAPKs phosphorylate cytoplasmic target 
or transcription factors on their serine or threonine residues followed by a 
proline. The diversity of MAPKKK increases the complexity of MAPK 
signaling cascade. In mammalian cells, three major MAPKs have been 
identified: the extracellular signal-regulated kinase 1 and 2 (ERKl/2), 
c-jun N-terminal kinase (JNK)，and p38 MAPK. ERKl/2 are strongly 
activated by growth stimuli and believed to be responsible for cell 
proliferation, while both JNK and p38 are strongly activated by stresses 
and inflammatory cytokines. p38 has shown to be critical for normal 
immune and inflammatory responses, such as the regulation of cytokine 
expression. Fig. 1.9 summarizes the upstream protein kinase and 
downstream substrates of the three major MAPKs (Roux and Blenis, 
2004). 
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Figure 1.9 An overview of ERKl/2, p38 and JNK MAPK cascades. 
The presence of extracellular stimuli leads to a sequential phosphorylation 
of MAPKKKs and MAPKKs. The activated MAPKK then activates 
specific MAPK through the dual phosphorylation on the threonine and 
tyrosine residues located in the activation loop. Each MAPK subsequently 
phosphorylates different transcription factors to mediate cellular 
responses (Roux and Blenis, 2004). 
1.10.2. Lipopolysaccharide and MAPKs in Macrophage Cytokine Expression 
Lipopolysaccharide (LPS) is the principal component of the outer 
membrane of gram-negative bacteria (e.g. E. coli) and being extensively 
used in many inflammation-related studies. The stimulation of 
macrophage by LPS result is an induction of cytokine expression, such as 
TNF-a and IL-6. The signal transduction mediated by LPS is well 
characterized. LPS，which forms complexes with a plasma LPS-binding 
protein, is first bound to and interact with the surface receptor CD 14 on 
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macrophage. This interaction leads to the activation of transmembrane 
toll-like receptor 4 (TLR4) and its accessory protein MD2, which 
subsequently activates the IKB kinase ( I K K ) - N F - K B pathway, and 
ERKl/2, p38 and JNK MAPKs. These signaling pathways eventually 
coordinate to induce cytokine secretion via the activation of various 
transcription factors, such as nuclear factor-kappa B (NF-KB) and 
activator protein-1 (AP-1) (Guha and Mackman, 2001). Both N F - K B and 
AP-1 have shown to be important in the macrophage expression of TNF-a 
and IL-6 (Dendorfer, 1996; Zagariya et ai, 1998). Figure 1.10 and 1.11 
show the transcription factor-binding sites and regulatory elements on the 
proximal promoter of IL-6 and TNF-a gene. 
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Figure 1.10 An overview of BL-6 promoter region -1200bp upstream 
from the transcription start site. The transcription factor AP-1, NF-IL6, 
c-fos, N F - K B , M R E , GATA and TATA binding site were identified on IL-6 
proximal promoter. Both NF-IL6 and MRE are components of serum 
response elements (SREs). NF-IL6, nuclear factor interleukin-6; MRE, 
multiple response elements (Keller et aL, 1996). 
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Figure 1.11 An overview of TNF-a promoter region -123bp 
upstream from the transcription start site. The transcription factor Ets, 
AP-1, NF-KB, NF-IL6，SP-1 and A P - 2 binding site were identified on 
TNF-a proximal promoter. Ets, Ets-domain transcription factor; SP-1, 
sequence-specific transcription factor-1 (Zagariya et aL, 1998). 
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1.10.3. Regulation of Macrophijge Cytokine Secretion 
1.10.3.1.ERK1/2 and p38 MAPK Pathway 
Both ERKl/2 and p38 MAPK have shown to play a key role in 
LPS-activated IL-6 expression in macrophages (Kim et ai, 2004， 
Carter and Monick et al.’ 1999), while the p38 MAPK is 
important for the post-transcriptional control of LPS-activated 
TNF-a production (Brook et ai, 2000). 
1.10.3.2. Arachidonic Acid Metabolism 
Arachidonic acid is the precursor of eicosanoids (prostaglandins, 
prostacyclin, thromboxanes, and leukotrienes) that plays 
important roles in regulating inflammatory responses (Leslie, 
2004). Previous studies have demonstrated that the secretion of 
both IL-6 and TNF-a is affected by arachidonic acid metabolism. 
An increased level of arachidonic acid was shown to stimulate 
IL-6 release from rat peritoneal macrophages, an effect mediated 
by increased prostacyclin production (Holladay et al., 1993). On 
the other hand, an increased level of arachidonic acid was shown 
to inhibit TNF-a release from murine peritoneal macrophages, 
possibly mediated through an increased levels of prostaglandin 
E2 at posttranscriptional level (Hubbard et al., 1993). However, 
the regulation of cytokine secretion in macrophage is complex 
and the signal transduction linked to TNF-a and IL-6 expression 
is still not fully understood. 
30 
1.11. Aim and Hypothesis 
Under physiological condition, macrophages are simultaneously 
interacting with both apoE from remote sources (exogenous apoE), i.e. 
plasma apoE and apoE produced by cellular apoE gene expression 
(endogenous apoE) (Ho et al” 2001). Previous studies have demonstrated 
differences in the biological functions between exogenous and 
endogenous apoE (Lin et al” 1999, Ho et al, 2001). In this project, we 
aim to investigate the effects of apoE isoform expression on the 
inflammatory responses in macrophages. The secretion of cytokine IL-6 
and TNF-a was the inflammatory response being focused in this study. It 
was hypothesized that a) endogenously expressed apoE would elicit 
isoform-dependent effects on cytokine secretion in macrophages, b) the 
isoform-dependent effects of endogenous apoE on cytokine secretion is 
associated with the changes of MAPK activities. Understanding the 
isoform-dependent effects of apoE on cytokine secretion in macrophage 
may further explain why carriers of different apoE isoforms have different 
susceptibility to inflammatory diseases, such as atherosclerosis. 
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Chapter 2 ： Materials and Methods 
Materials 
2.1. Culture of ApoE-isoform-expressing .T774A.1 Macrophage Cell Line 
2.1.1. Mouse Peritoneal Macrophage Cell Line J774A.1 
It was purchased from American Type Culture Collection (Manassas, VA， 
USA) 
2.1.2. High Glucose Dulbecco's Modified Eagle's Medium (DMEM) 
It was prepared by dissolving powder which contains 4,500 mg/L 
D-glucose, 4 mM L-glutamine, 110 mg/L sodium pyruvate and 4 mg/L 
pyridoxine HCl (Gibco BRL Life Technologies, Inc, Carlsbad, CA, USA) 
in double distilled water and each liter was buffered with 3.7 g sodium 
bicarbonate (Sigma, St. Louis, MO, USA). The pH of the medium was 
then adjusted to 7.2-7.4 by 6 N HCl (Sigma, St. Louis, MO, USA). It was 
finally sterilized by filtration through 0.22)Lim filter (Millipore, Billerica, 
Mass, USA) and stored at 4 °C until use. 
2.1.3. Fetal Bovine Serum (FBS) 
It was purchased from Gibco BRL Life Technologies, Inc. (Carlsbad, CA, 
USA). FBS was added to the DMEM medium to a final concentration of 
10 % (v/v). 
2.1.4. Penicillin-Streptomycin Antibiotic Mixture (P/S) 
It was purchased from Gibco BRL Life Technologies, Inc. (Carlsbad, CA, 
USA) as lOOX stock solution, which contains 10,000 units/ml penicillin G 
sodium and 10,000 i^g/ml streptomycin sulfate in 0.85 % saline. The 
antibiotic mixture was added to the DMEM medium to a final 
32 
concentration of 1 % (v/v) for preventing bacterial and fungal 
contamination of cells. 
2.1.5. Phosphate-Buffered Saline (PBS) 
The chemicals were purchased from Sigma (St. Louis, MO, USA). The 
stock lOX PBS solution was prepared by dissolving 80 g of sodium 
chloride (NaCl) (1370 mM), 2 g of potassium chloride (KCl) (27 mM), 
14.4 g of dibasic sodium phosphate (NazHPCU) (100 mM) and 2.4 g of 
monobasic potassium phosphate (KH2PO4) (20 mM) in 1 liter double 
distilled water. The working IX PBS was prepared by diluting 100 ml of 
lOX PBS with 900 ml double distilled water. 
2.1.6. Neomycin (G418 Sulfate) 
It was purchased from Merck (San Diego, CA, USA). 
2.1.7. Cell Culture Wares 
) 
The 75 cm flasks, 100 mm dishes and centrifuge tubes were purchased 
from Iwaki (Chiba, Japan) while the cell scraper was purchased from SPL 
Life Sciences (Pocheon City, Korea). 
2.2. RNA Extraction and Reverse Transcription-Polvmerase Chain 
Reaction (RT-PCR) 
2.2.1. Reagent for RNA Extraction 
1) Diethyl Pyrocarbonate (DEPC) 
It was purchased from Amersham Biosciences (Buckinghamshire, UK). 
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2) DEPC-treated Double Distilled Water 
The 0.1 % (v/v) DEPC water was prepared by adding DEPC 
(Amersham Biosciences) to double distilled water at 1:1000 ratio. It 
was stirred overnight to disperse the DEPC and autoclaved at 121°C 
for 20 minutes to vaporize the remaining DEPC. 
3) TRI Reagent and l-bromo-3-chloropropane (BCP) 
They were purchased from Molecular Research Center, Inc. 
(Cincinnati, OH, USA). 
4) Spectrophotometric Cuvette 
The UVette® used for RNA concentration measurement was purchased 
from Eppendorf (Hamburg, Germany). 
2.2.2. Reagents for Reverse Transcription 
1) Oligo(dT)i5 
It was synthesized by Invitrogen, Life Technologies (Carlsbad, CA， 
USA). The lyophilized powder was reconstituted in autoclaved double 
distilled water to 100 |iM. 
2) Reverse Transcriptase and Reaction Buffer 
RevertAidTM H Minus M-MuLV Reverse Transcriptase (200 U/|j.1) and 
5X reaction buffer were purchased from Fermentas (Hanover, MD, 
USA). The reverse transcriptase was supplied in buffer containing 50 
mM Tris-HCl (pH 8.3), 0.1 M NaCl, 1 mM EDTA，5 mM DTT, 0.1% 
(v/v) Triton X-100, and 50% (v/v) glycerol, while the 5X reaction 
buffer contained 250 mM Tris-HCl (pH 8.3)，250 mM KCl, 20 mM 
MgCh and 50 mM DTT. 
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3) Ribonuclease Inhibitor 
RNAGuard ribonuclease inhibitor (30 U/)j.1) isolated from human 
placenta was purchased from Amersham Biosciences 
(Buckinghamshire, UK). It was supplied in buffer containing 20 mM 
H E P E S - K O H , pH 7.6，50 m M KCl，5 m M DTT, and 5 0 % (v/v) 
glycerol. 
4) Deoxyribonucleoside Triphosphate (dNTP) Mix 
The dNTP mix (10 mM) were purchased from Amersham Biosciences 
(Buckinghamshire, UK). 
2.2.3. Reagents for Polymerase Chain Reaction (PGR) 
1) Taq DNA Polymerase 
Taq polymerase isolated from Thermus aquaticus (5 U/|^l) was 
purchased from Amersham Biosciences (Buckinghamshire, UK). The 
lOX reaction buffer supplied with Taq polymerase contained 100 mM 
Tris-HCl (pH 9.0), 15 mM MgCb solution and 500 mM KCl. 
2) Dimethyl Sulfoxide (DMSO) 
It was purchased from Sigma (St. Louis, MO, USA). 
3) Primer Pairs 
All designed oligonucleotide primers were synthesized by Invitrogen, 
Life Technologies (Carlsbad, CA, USA). The lyophilized primer pairs 
were reconstituted in autoclaved double distilled water to 100 foJVI. The 
10 i^ M working solution was prepared by 10-fold dilution of the 
lOO^iM stock solution with autoclaved double distilled water. 
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2.2.4. Reagents for Agarose Gel Electrophoresis 
1) Agarose 
It was purchased from Sigma (St. Louis, MO, USA). All DNA 
fragments were separated on 1 % (w/v) agarose gel. 
2) Electrophoresis Apparatus 
Wide mini-sub cell GT systems were purchased from Bio-Rad 
Laboratories (Hercuk s, CA, USA). 
3) 5XTris-borate-EDTA (TBE) Electrophoresis Buffer 
Stock 5X TBE buffer was prepared by dissolving 54 g of Tris base 
(0.45 M) (Amersham Biosciences, Buckinghamshire, UK), 27.5 g of 
boric acid (0.45 M) (Sigma, St Louis, MO, USA) and 20 ml of 0.5 M 
EDTA (Sigma, St Louis, MO, USA) in 1 liter double distilled water 
with pH calibrated to 8.0 using 6 N HCl (Sigma) or 2 M NaOH (ICN 
BioMedicals Inc, Irvine, CA, USA). The IX working solution was 
prepared by 5-fold dilution of the stock TBE. 
4) 6X Loading Dye Solution 
It was prepared by mixing 0.25 % (w/v) bromophenol blue (Amersham 
Biosciences, Buckinghamshire, UK), 0.25 % (w/v) xylene cyanol FF 
(ICN BioMedicals Inc, Irvine, CA, USA), and 40 % (v/v) glycerol 
(Amersham Biosciences, Buckinghamshire, UK) in autoclaved double 
distilled water. 
5) Ethidium Bromide (EtBr) 
It was purchased from Amresco (Solon, Ohio, USA) 
6) DNA Ladder Marker 
The 100 bp and 1 kbp DNA markers were purchased from Fermentas 
36 
(Hanover, MD, USA}. The working solution was prepared by mixing 
the stock DNA markers, 6X loading dye and autoclaved double 
distilled water in a ratio of 1:1:4. For each agarose gel, 2 of working 
DNA ladder marker was loaded. 
2.3. Protein Extraction and Quantification 
2.3.1. Cell Lysis Buffer 
It was prepared by mixing 1 % SDS (Amersham Biosciences, 
Buckinghamshire, UK), 1 mM sodium orthovanadate (Na3V04) (Sigma, 
St. Louis, MO, USA), 10 mM Tris (pH 7.4) (Amersham Biosciences), 21 
(ig/ml aprotinin (Amersham Biosciences, Buckinghamshire, UK), 5 )j.g/ml 
leupeptin (Amersham Biosciences, Buckinghamshire, UK), 1 mM 
phenylmethylsulfonyl fluoride (PMSF) (Amersham Biosciences, 
Buckinghamshire, UK) and 5 mM MgCh (Amersham Biosciences, 
Buckinghamshire, UK) in autoclaved double distilled water. 
2.3.2. Detergent Compatible (DC) Protein Assay Kit 
It was purchased from Bio-Rad Laboratories (Hercules, CA, USA) for 
determining the protein (concentration of sample. 
2.3.3. Bovine Serum Albumin (BSA) 
It was purchased from Sigma (St. Louis, MO, USA). 
2.3.4. Spectrophotometric Cuvette 
The plastic cuvette used for protein concentration measurement was 
purchased from Sarstedt (Numbrecht, Germany). 
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2.4. Enzyme-linked Immunosorbent Assay (ELISA) 
2.4.1. Ninety-six-well Immunolon Plates 
It were purchased from Nalge Nunc International (Rochester, NY, USA). 
2.4.2. Recombinant ApoE Protein for Standard Curve 
The recombinant human apoE3 protein produced by baculovirus-mediated 
expression in the Spodoptera frugiperda insect cell line was purchased 
from Research Diagnostics, Inc. (Flanders, NJ, USA). 
2.4.3. Coating Antibody 
Goat polyclonal anti-human apoE antibody (BioDesign, Saco, ME, USA), 
rat anti-mouse IL-6 monoclonal antibody (R&D Systems Inc., MN, USA) 
and rabbit anti-mouse TNF-a polyclonal antibody (Pierce Biotechnology, 
Inc., Rockford, USA) were supplied at a concentration of 1 mg/ml, 500 
l^g/ml and 1.01 mg/ml respectively. 
2.4.4. Secondary Antibody 
Goat biotin-conjugated anti-human apoE antibody (BioDesign, Saco, ME, 
USA), rat biotin-conjugated anti-mouse IL-6 monoclonal antibody (Pierce 
Biotechnology, Inc., Rockford, USA) and rabbit biotin-conjugated 
anti-mouse TNF-a polyclonal antibody (Pierce Biotechnology, Inc., 
Rockford, USA) were supplied at a concentration of 0.8 mg/ml, 0.5 
mg/ml and 0.25 mg/ml respectively. 
2.4.5. Conjugation Enzyme and Substrate 
The conjugate enzyme, avidin peroxidase and its substrate, 
2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) were 
purchased from ICN BioMedicals Inc. (Irvine, CA, USA). 
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2.4.6. Hydrogen Peroxide, 30% (v/v) (H2O2) 
It was purchased from Sigma (St. Louis, MO, USA). 
2.4.7. Coating Buffer 
It was IX PBS prepared by 10-fold dilution of stock lOX PBS (mentioned 
in section 2.1.5) 
2.4.8. Washing Buffer 
It was prepared by adding 0.02 % (v/v) Tween 20 (USB) in IX PBS. 
2.4.9. Blocking Buffer 
It was prepared by mixing 1% BSA (w/v) (Sigma) in IX PBS. 
2.5. Western Blotting 
2.5.1. 30 % (w/v) Acrylamide / Bis-acrylamide Solution, 37.5:1 
It was purchased from Bio-Rad Laboratories (Hercules, CA, USA). 
2.5.2. Stacking Gel Buffer 
It was a 0.5 M Tris-HCl buffer (Amersham Biosciences) containing 0.4 % 
SDS (Amersham Biosciences) adjusted to pH 6.8. 
2.5.3. Running Gel Buffer 
It was a 1.5 M Tris-HCl buffer (Amersham Biosciences) containing 0.4 % 
SDS (Amersham Biosciences) adjusted to pH 8.8. 
2.5.4. Ammonium Persu丨fate (APS) 
It was purchased from USB (Swampscott，MA, USA). 
2.5.5. N,N,N',N'-Tetra-methylethylenediamine (TEMED) 
It was purchased from Bio-Rad Laboratories (Hercules, CA, USA). 
2.5.6. 4X Sample Loading Buffer 
It was prepared by mixing 0.4 ml of 1% (w/v) bromophenol blue 
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(Bio-Rad Laboratories, Hercules, CA, USA), 1 ml of 0.5 M Tris-HCl 
(Amersham Biosciences) at pH 6.8，1.6 ml of glycerol (Amersham 
Biosciences), 1.6 ml of 20 % (w/v) SDS (Amersham Biosciences), 4.2 ml 
of double distilled water and 0.3 ml of P-mercaptoethanol (Bio-Rad, 
Hercules, CA, USA). 
2.5.7. Prestained Protein Standard (Broad Range) 
It was purchased from Bio-Rad Laboratories (Hercules, CA, USA), which 
consists of eight prestained proteins with known molecular weight. 
2.5.8. Tris-Glycine-SDS Electrophoresis Buffer 
The stock lOX electrophoresis buffer was prepared by dissolving 30 g of 
Tris base (0.25 M) (Amersham Biosciences), 144.1 g of glycine (1.92 M) 
(Amersham Biosciences, Buckinghamshire, UK) and 1 % (w/v) SDS 
(Amersham Biosciences) in 1 liter double distilled water with pH adjusted 
to 8.3 by 6 N HCl (Sigma). The IX working buffer was prepared by 
10-fold dilution of the stock buffer. 
2.5.9. Coomassie Blue Staining and Destaining Solution 
The staining solution was prepared by mixing 0.25 g of Coomassie R-250 
(Bio-Rad, Hercules, CA, USA), 10 ml of acetic acid (Sigma, St. Louis, 
MO, USA), 50 ml of methanol (Sigma, St. Louis, MO, USA) and 50 ml 
of double distilled water. The destaining solution was prepared by mixing 
the acetic acid, methanol and double distilled water at a ratio of 1:3:10. 
2.5.10. lOX Tris-Glycine Buffer 
The stock lOX Tris-glycine buffer was prepared by dissolving 30 g of Tris 
base (0.25 M) (Amersham Biosciences) and 140 g of glycine (1.9 M) 
(Amersham Biosciences� in 1 liter double distilled water. 
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2.5.11. Tris-Glycine-methanol Transfer Buffer 
It was freshly prepared by mixing methanol, the stock lOX Tris-glycine 
buffer and double distilled water at a ratio of 1:1:8. 
2.5.12. PolyScreen® PVDF Hybridization Transfer Membrane 
It was purchased from PerkinElmer (Boston, MA, USA). 
2.5.13. Electrophoresis and Transfer Apparatus 
Mini-Protein III electrophoresis cell systems were purchased from 
Bio-Rad Laboratories (Hercules, CA, USA). 
2.5.14. lOX Tris-buffered Saline (TBS) 
The stock lOX TBS was prepared by dissolving 24.2 g of Tris base (0.2 M) 
(Amersham Biosciences) and 80 g of NaCl (1.37 M) (Sigma) in 1 liter 
double distilled water with pH adjusted to 7.6 by 6 N HCl (Sigma). 
2.5.15. TBS-Tween (Washing Buffer) 
It was prepared by adding 1 ml of Tween-20 (USB, Swampscott, MA, 
USA) in 100 ml stock lOX TBS and 900 ml double distilled water. 
2.5.16. 5% Nonfat Milk Solution (Blocking Buffer) 
It was prepared by dissolving 5 % (w/v) nonfat milk powder in washing 
buffer. 
2.5.17. ECL™ Western Blottii g Detection Reagents 
It was purchased from Amersham Biosciences (Buckinghamshire, UK). 
2.5.18. X-ray film 
It was purchased from Roche Applied Science (Indianapolis, IN, USA). 
2.5.19. Stripping Solution 
It was prepared by mixing 29.22 g of NaCl (0.5 M) (Sigma) with 30 ml of 
acetic acid (30 %，v/v) (Sigma) in 1 liter double distilled water. 
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2.5.20. Primary Antibodies 
Rabbit polyclonal anti-mouse extracellular-regulated kinase 1/2 (ERK 
1/2), mouse polyclonal anti-mouse phospho-ERK 1/2 (pERK 1/2)，rabbit 
polyclonal anti-mouse p38 and rabbit polyclonal anti-mouse phospho-p38 
were purchased from Cell Signaling Technology (Beverly, MA, USA). 
Goat polyclonal anti-human apoE antibody was purchased from 
BioDesign (Saco, ME, USA). Mouse monoclonal anti-GAPDH antibody 
was purchased from Chemicon International Inc. (Termecula, CA，USA). 
2.5.21. Secondary Antibodies 
Peroxidase-linked anti-rabbit, anti-goat and anti-mouse IgG were 
purchased from Cell Signaling Technology (Beverly, MA, USA), Santa 
Cruz Biotechnology (Santa Cruz, CA, USA) and Zymed Laboratories, Inc. 
(San Francisco, CA, USA), respectively. 
2.6. LPS Treatment 
2.6.1. Hemacytometer 
Cell number was determined by direct cell count using hemacytometer 
purchased from Sigma (St. Louis, MO, USA). 
2.6.2. Microscope 
Cell count was performed under a light microscope from Olympus 
America Inc. (Melville, NY, USA) with a magnification of lOOx. 
2.6.3. Serum Free Medium 
It was purchased from Cambrex (Pittsburgh, PA, USA) 
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2.6.4. Lipopolysaccharide (LPS) 
It was produced by E. coli 026:B6 and purchased from Sigma (St. Louis, 
MO, USA). 
2.6.5. Recombinant Human ApoE2, ApoE3 and ApoE4 
They were produced by E. coli and purchased from Research Diagnostics, 
Inc. (Flanders, NJ, USA). 
2.7. MAPK Inhibitor Experiment 
2.7.1. MAPK Inhibitors 
U0126 (MEKl/2 inhibitor) and SB 203580 (p38 inhibitor) were 
purchased from Merck (San Diego, CA, USA). 
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Methods 
2.8. Study on the Effect of Endogenously Expressed ApoE Isoforms on 
Macrophage Cytokine Secretion 
2.8.1. Establishment of ApoE-isoform-expressing Macrophages 
Macrophages with stable expression of human apoE2, apoE3 and apoE4 
were established by our lab fellow. In brief, the human apoE3 cDNA was 
cloned into the mammalian expression vector pcDNA3.1(+) (Invitrogen, 
Carlsbad, CA, USA), flanked within the Kpnl and Xbal cloning sites. The 
apoE2 and apoE4 expressing plasmids were then constructed by 
site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) using 
primers designed with the single point mutation at the middle. The 
apoE-isoform expressing plasmid was eventually transfected into mouse 
peritoneal macrophage cell line J774A.1, a cell line that do not have 
native apoE expression. Neomycin (700 |ig/ml) was applied for two 
weeks to select macrophages with stable expression of apoE isoform. 
Stable cell lines were finally maintained in high glucose DMEM 
supplemented with 10% FBS, 1% P/S and 700)j.g/ml neomycin, and 
incubated at 37°C chamber in a humidified atmosphere of 5% CO2. 
Subculture was performed twice a week. Cells were also kept as frozen 
stock in freezing medium containing 10% FBS and 10% DMSO, and 
stored in liquid nitrogen. 
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2.8.2. Semi-quantification of ApoE mRNA Level by RT-PCR 
1) Isolation of Total RNA 
Control and apoE isoform-expressing cells (1 x IC/) cells/dish) were 
seeded in 100 mm culture dishes containing growth medium (10% 
FBS, 1% P/S in high glucose DMEM). After incubating at 37°C for 24 
hours, cells were homogenized by adding 1 ml of TRI reagent directly 
to the culture dishes and incubated at room temperature for 5 minutes 
to allow complete dissociation of nucleoprotein complexes. Cell 
lysates were then scraped down and transferred to a 1.5 ml 
microcentrifuge tube. 100 )li1 BCP was then added to the 
microcentrifuge tube, followed by vigorous shaking for 15 seconds. 
After incubation at rc om temperature for 10 minutes, the mixture was 
centrifuged at 12,000 x g for 15 minutes at 4°C for phase separation. 
Most RNA was distributed in the colorless upper aqueous phase 
whereas DNA and proteins remained in the interphase and organic 
phase respectively. Therefore the upper aqueous layer was collected 
and transferred to another new 1.5 ml microcentrifuge tube. 0.5ml 
isopropyl alcohol was then added to precipitate RNA from the aqueous 
phase and it was stored at - 2 0 � C overnight. On the following day, RNA 
was pelleted by centrifugation at 12,000 x g for 15 minutes at 4�C，and 
the supernatant was aspirated. The RNA pellets were subsequently 
washed with 1 ml 75% ethanol and further centrifuged at 12,000 x g 
for 5 minutes at 4°C. Ethanol was then removed and the RNA pellets 
were air-dried for 20 minutes at room temperature. The RNA pellets 
were finally resuspended in 50 i^l of DEPC-treated water. RNA 
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concentration was quantified at 260 nm by BioPhotometer (Eppendorf, 
Hamburg, Germany). The purity was estimated by the ratio of 
A26()/A28o and only samples with values greater than 1.7 were used for 
further experiments. The integrity of the isolated RNA was checked by 
gel electrophoresis on 1 % agarose gel and two predominant bands of 
18S (~2 kb) and 28S ( -5 kb) ribosomal RNA in a ratio of 1:2 should be 
- visualized. 
2) RT-PCR 
Total RNA extracts from the control and apoE isoform-expressing cells 
were used as templates for producing cDNA using RevertAid™ H 
Minus M-MuLV Reverse Transcriptase. RT reactions were performed 
using 5 |j.g of total cellular RNA per 20 fj.1 reaction mixture following 
the manufacturer's protocols. In brief, the template RNA was first 
mixed with 1 |li1 of 100 mM oligo(dT)i5 and incubated at 70°C for 5 
minutes to denature the RNA. Then, 4 i^l of 5X reaction buffer, 2 \x\ of 
lOmM dNTP mix, 0.5 fil (15 units) of RNAGuard ribonuclease 
inhibitor and an appropriate amount of DEPC-treated water were 
added to the mixture to make up a final volume of 19.8 )li1. After a 
further incubation at 3 7 � C for 5 minutes, 0.2 |j,l of M-MuLV reverse 
transcriptase (200 U/|^l) was finally added. The 20 )al reaction mixture 
was incubated at 42°C for 90 minutes for cDNA synthesis, followed by 
70°C for 10 minutes to inactivate reverse transcriptase and then cooled 
to 4°C. The cDNA synthesized was then 10-fold diluted with 
autoclaved double distilled water. Equal volume of cDNA from the 
control and apoE-isoform-expressing cells were finally used as DNA 
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template for PGR amplification of APOE gene, using the primer pairs, 
reagents and PGR conditions as follows (Table 2.1 and 2.2): 
Table 2.1: Primer sequences for amplification of apoE gene 
Primer Sequence Product Size 
Forward 5'ACGCGGGCACGGCTGTCCAA 3' 
430 bp Reverse 5’ TCCTTCACCTCGTCCAGGCG 3' 
Table 2.2: Components in the PGR amplification of apoE gene 
Component Volume (|.il) 
lOX reaction buffer 2.5 
10 mM dNTP mix 0.5 
10 i-iM Forward primer 0.5 
10 |iM Reverse primer 0.5 
DMSO 1.0 
cDNA 5 
Autoclaved H2O 14.8 
Taq DNA polymerase 0.2 
Total: 25 
2.8.3. Determination of ApoE Protein Expression Level by fiLISA and 
Western Blot 
Control and apoE isoform-expressing cells (1 x lO'' cells/dish) were 
seeded and grew overnight at 37°C in 100 mm culture dishes containing 
growth medium (10% FBS, 1% P/S in high glucose DMEM). The growth 
medium was replaced with 5ml serum free medium after overnight 
incubation and the medium and cell lysates were collected after 24 hours 
incubation. In brief, the medium was centrifuged at 2,000 rpm for 5 
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minutes to remove any cell debris before quantification of apoE by 
ELISA. After the collection of medium, cells on 100mm dish were first 
washed with PBS twice. lOOfil lysis buffer was added to each dish and the 
cell lysates were transferred to 1.5ml microfuge tube, which was frozen 
at -20°C overnight. The cell lysates were then boiled at 95°C for 10 
minutes and centrifuged at 12,000 x g for 7 minutes at 4°C. The total 
proteins in resulting supernatants were quantified by DC protein assay kit 
before subjected to quantification of apoE protein by ELISA. 
1) Quantification of Total Proteins 
The total protein contents of the cell lysates were estimated by the DC 
protein assay kit. BSA standard of 0.2 mg/ml, 0.4 mg/ml, 0.6 mg/ml, 
0.8 mg/ml and 1 mg/ml were prepared from 1 mg/ml BSA stock 
solution by serial dilution. BSA standards or ten-fold diluted protein 
samples (12.5 ^1) were mixed with 62.5 )li1 of reagent A, followed by 
the addition of 500 |il of reagent B in a 1-ml plastic cuvette. The 
reaction mixtures were then incubated at room temperature for 15 
minutes and their absorbance at 750 nm was recorded using the dye 
reagent as a blank. Both BSA standards and protein samples were 
measured in duplicate. The concentrations of the protein samples were 
determined spectrophotometrically by BioPhotometer. 
2) ELISA 
Expression levels of human apoE isoforms were quantified by 
sandwich-type ELISA. Ninety-six-well immunolon plates were coated 
with 50 1^1 of goat anti-human apoE primary antibody (4)ig/ml) in 
coating buffer overnight. The coated plates were washed 3 times with 
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washing buffer (200 jil/well) and blocked with blocking buffer (200 
l^l/well) at room temperature for 2 hours. The plates were then washed 
3 times with washing buffer (200 i^l/well). The recombinant apoE 
protein was then 2-fold serial diluted in serum free medium to obtain a 
linear standard curvo ranged from 20ng to 1.25ng. 100)li1 of the 
recombinant apoE protein standard, 100)liI of media and 100fig cell 
lysates were added to wells in duplicate and incubated overnight at 4°C. 
Plates were washed 3 times with washing buffer (200 |il/well) and then 
incubated with 100 goat biotin-conjugated anti-human apoE 
secondary antibody (l|j.g/ml) at overnight at 4°C. After washing 3 
times with washing buffer (200 |il/well)，avidin peroxidase in washing 
buffer (100 ^il/well) at a concentration of 2.5 \x.glm\ was added and 
incubated for 1 hour at room temperature. The plates were then washed 
3 times with washing buffer (200 |^l/well). Finally, 0.001 volume of 30 
% H2O2 was added to 1 volume of ABTS and 100 was added to each 
well. The plates were wrapped in aluminum foil and color 
development was allowed to proceed for 10 minutes. The plates were 
finally read by the 3550 microplate reader (Bio-Rad, Hercules, CA, 
USA) at a wavelength of 405 nm. The apoE protein levels were finally 
calculated by comparison to their respective standard curve and 
expressed as ng/ml for media and ng/|_ig total proteins for cell lysates 
using serum free medium only as blank. 
3) Western Blot 
The media and cell lysates were resolved by 12% SDS-PAGE. Table 
2.3 shows the composition of a 12% SDS-polyacrylamide gel. Protein 
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samples were prepare d by mixing an equal amount of cell lysates (50 
l_ig) and media (40|il) with 4X sample loading buffer and boiled for 10 
minutes. Five microliters of prestained protein standards were also 
loaded as molecular weight marker. The gel was then run at 100 volts 
for 2 hours. 
Table 2.3: Composition of 12% SDS-polyacryJamide gel 
5 % Stacking Gel 12 % Running Gel 
Reagent 
(5 ml) (5 ml) 
30% Acrylamide Stock 0.825 ml 2 ml 
Stacking Gel Buffer 1.25 ml -
Running Gel Buffer - 1.25 ml 
Distilled Water 2.875 ml 1.7 ml 
10 % APS 50 |al 50 
TEMED 3.3 |al 3.3 i^l 
After electrophoresis, the stacking gel was removed. The gel was 
rinsed briefly with distilled water and immersed in transfer buffer. One 
piece of PolyScreen® PVDF hybridization transfer membrane, two 
pieces of 3 MM Whatmann chromatography papers (Kent, UK) and 
two pieces of sponge were also pre-wetted with transfer buffer. They 
were assembled in the wet blotting apparatus from Bio-Rad 
Laboratories (Hercules, CA, USA). The proteins on the gel were then 
electroblotted onto the PolyScreen® PVDF hybridization transfer 
membrane at 100 volts for 2 hours. After the transfer, membrane with 
transferred proteins was incubated in blocking buffer with constant 
shaking for 1 hour at room temperature to block the non-specific sites. 
At the same time, the gel was stained with Coomassie Blue for 30 
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minutes and then destained. After blocking, the membrane was 
incubated with goat anti-human apoE antibody at 10000-fold dilution 
in blocking buffer at 4°C overnight. After blotting with the primary 
antibody, the membrane was washed for 15 minutes with three changes 
of washing buffer. After washing, the membrane was incubated with 
horseradish peroxidase-linked anti-goat antibody at 5000-fold dilution 
in blocking buffer for 1 hour at room temperature. The membrane was 
then washed for 15 minutes with three changes of washing buffer and 
subjected to enhanced chemiluminescent (ECL™) Assay. 
In ECIJm assay, equal volumes of ECL™ detection reagent 1 was 
freshly mixed with detection reagent 2 and pipetted onto the membrane. 
For each cm^ of membrane, 10 \x\ of detection reagent was applied. 
The membrane was wrapped with cling wrap so that the detection 
reagent can evenly cover on the surface of the membrane and was 
allowed to react for 1 minute. The membrane covered with cling wrap, 
with the protein side down, was placed in the film cassette which 
contained a sheet of X-ray film placed inside in advance. The film was 
allowed to expose in the dark. Finally, the film was developed and the 
immunoreactive bands could be visualized on the X-ray film. 
2.8.4. LPS Treatment 
Control and apoE isoform-expressing cells (1 x lO*" cells/dish) were 
seeded in 100 mm culture dishes containing growth medium (10% FBS, 
1% P/S in high glucose DMEM). After incubating at 37�C for 24 hours, 
the growth media for LPS-treated groups were replaced with fresh media 
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containing lOOng/ml LPS, while PBS instead of LPS was added to the 
control group. After 6 hours of incubation, the cellular morphologies of 
apoE isoform-expressing cells, with or without LPS treatment were 
studied by light microscopy (Olympus IX-71, Melville, NY, USA) and 
photographed. The media and cell lysates were collected using method as 
described in section 2.8.3• The secretion level IL-6 and TNF-a in the 
media was then quantified by ELISA while the total expression and 
activity of MAPK in the cell lysates were detected by Western blot. The 
method for ELISA and Western blot was similar to that described in 
section 2.8.3.，except the primary and secondary antibody used were 
different (Table 2.4 and Table 2.5). In ELISA, the basal IL-6 and TNF-a 
level in control cells before LPS activation was set as one and their 
relative amount in other cells were expressed as fractions of that of 
control cells. In Western blot, after target protein detection, the 
membranes were striped in stripping solution for 10 minutes and washed 
for 10 minutes in washing buffer. They were then incubated with GAPDH 
antibody to serve as the protein loading control. The comparison of target 
protein amount was done by scanning the density of immunodetected 
bands using Image J software (Research Services Branch, National 
Institute of Mental Health, Bethesda, MD. USA). The band intensities of 
target proteins were expressed as a fraction to the control cell line before 
LPS activation. 
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Table 2.4: Coating concentration of primary and secondary 
antibodies for IL-6 and TNF-a quantification 
Coating Antibody Concentration 
Rat anti-mouse IL-6 antibody 1 ^g/ml Primary 
Rabbit anti-mouse TNF-a antibody 2 ng/ml 
Secondary Rat anti-mouse IL-6 antibody 0.5 |.ig/ml 
(Biotin-conjugated) Rabbit anti-mouse TNF-a antibody 1 ^g/ml 
Table 2.5: Antibodies for apoE and MAPKs detection 
Primary Secondary Molecular 
Target Protein Source Antibody Antibody Weight 
Dilution* Dilution* (kDa) 
ApoE Goat 1:10000 (5%) 1:5000 (5%) 34 
GAPDH Mouse 1:10000 (5%) 1:5000 (5%) 38 
ERKl/2 Rabbit 1:1000 (3%) 1:2000 (3%) 42/44 
Phospho-ERKl/2 Mouse 1:1000(3%) 1:1000 (3%) 42/44 
p38 Rabbit 1:1000 (3%) 1:2000 (3%) 40 
Phospho-p38 Rabbit 1:1000(3%) 1:1000 (3%) 40 
*: The percentage indicated in blankets represents the amount (w/v) 
of nonfat dried milk in washing buffer. 
2.8.5. MEKl/2 Inhibitor Experiment 
Control and apoE isoform-expressing cells (1 x K/’ cells/dish) were 
seeded in 100 mm culture dishes containing growth medium (10% FBS, 
1% P/S in high glucose DMEM). After incubating at 37°C for 24 hours, 
the growth media for MEKl/2 inhibitor-treated group were replaced with 
fresh media containing 50|iM U0126, while the control groups were 
replaced with fresh media containing 1.25^1/ml DMSO. Both DMSO and 
U0126 were preincubated for 30 mins before lOOng/ml LPS were added 
in both groups. 
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After 6 hours of incubation in LPS, the media and cell lysates were 
collected using method as described in section 2.8.3. The secretion level 
of IL-6 and TNF-a in the media was then quantified by ELISA using 
method described in section 2.8.3. The IL-6 and TNF-a level in control 
. cells without MEKl/2 inhibitor was set as one and their relative amount 
in other cells were expressed as fractions of that of control cells. 
2.8.6. p38 Inhibitor Experiment 
Control and apoE isoform-expressing cells (1 x 10^ cells/dish) were 
seeded in 100 mm culture dishes containing growth medium (10% FBS, 
1% P/S in high glucose DMEM). After incubating at 37°C for 24 hours, 
the growth media for p38 inhibitor-treated group were replaced with fresh 
media containing lO^iM SB 203580, while the control groups were 
replaced with fresh media containing 0.25|Lil/ml DMSO, Both DMSO and 
SB 203580 were preincubated for 1 hour before lOOng/ml LPS were 
added in both groups. 
After 6 hours of incubation in LPS, the media and cell lysates were 
collected using method as described in section 2.8.3. The secretion level 
of IL-6 and TNF-a in the media was then quantified by ELISA using 
method described in section 2.8.3. The IL-6 and TNF-a level in control 
cells without p38 inhibitor was set as one and their relative amount in 
other cells were expressed as fractions of that of control cells. 
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2.9. Study on the Effect of Exogenous ApoE Isoform on Macrophage 
Cytokine Secretion 
Vector control J774A.1 cells without apoE expression was used in this 
study. Cells (1 x l l / cells/dish) were seeded in 100 mm culture dishes 
containing growth medium (10% FBS, 1% P/S in high glucose DMEM). 
After incubating at 37°C for 24 hours, the growth media for LPS-treated 
groups were replaced with serum free media containing lOOng/ml LPS, 
while PBS instead of LPS was added to the control group. Recombinant 
human apoE2, apoE3 and apoE4 were added at 5 |ig/ml to the 
corresponding dish and equal volume of PBS was added in the control. 
After 6 hours of incubation, the cells and media were collected. The 
secretion level of TNF-a and IL-6 in media were determined by ELISA 
while the activation status and total expression of ERKl/2 and p38 
MAPKs were determined by Western blot, using method as described in 
section 2.8.3. 
2.10. Statistical Analysis 
Kruskal-Wallis one way analysis of variance (ANOVA) on ranks was 
performed to detect statistical differences among experimental groups. 
Student-Newman-Keuls Method was performed for comparison among 
apoE isoforms. A significance of difference was determined at the /?<0.05 
level. 
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Chapter 3: Results 
Changes of Inflammatory Properties Associated with Endogenous ApoE 
Isoforms Expression in Macrophages 
3.1. Characterization of ApoE-isoform-expressing Macrophages 
The apoE isoform-expressing plasmids were successfully constructed by 
our lab fellows. In these plasmids, the apoE cDNA expression was driven 
by the cytomegalovirus (CMV) immediate-early promoter. Automated 
DNA sequencing confirmed that the plasmids contained a C to T mutation 
in apoE2 construct and a T to C mutation in apoE4 construct. The apoE 
isoform-expressing constructs, together with the control vector were then 
transfected into the mouse peritoneal macrophage cell line J774A.1, a cell 
line that does not have endogenous apoE expression. The transfected cells 
were selected in neomycin-containing media and expanded into stable 
polyclonal cell lines. 
3.1.1. Cell Lines with Stable Expression of ApoE Isoforms 
The expression of apoE isoforms was detected by Western blot and 
RT-PCR (Figure 3.1)，and was quantified by a sandwich-type ELISA. 
Table 3.1 shows the concentration of apoE isoforms in the whole cell 
lysates and media. ApoE isoforms were successfully expressed in the 
stable cell lines by comparing to the control cells. ApoE3-expressing cells 
showed a significant higher expression of apoE than apoE2- and 
apoE4-expresssing cells. 
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Figure 3.1. ApoE protein and mRNA expression in macrophages. 
Cells (1 X I f / ) were grown in serum free medium for 24 hours, and the 
cell lysates, media and RNA were harvested. For immunoblotting, equal 
amounts of cell lysates (lOOfig) and media (40)^1) were loaded onto 
SDS-12% polyacrylamide gels. ApoE was detected with anti-human apoE 
antibody and ECL™ assay. For RT-PCR, equal amount of RNA (S^ig) 
was subjected to reverse transcription and the apoE gene was then 
amplified from the cDNA formed using specific primers. The PGR 
products were resolved by 1% agarose gel. 
Table 3.1 ELISA quantification of the expression level of apoE 
isoforms in stable cell lines. Cells (1 x lO^) were grown in serum free 
medium for 24 hours, and the cell lysates and media were harvested. 
Equal amounts of cell lysates (100|ig) and equal volumes of media (100|LI1) 
were added into each well of ELISA plates coated with anti-human apoE 
antibody. The concentration of apoE isoforms was then calculated from 
the standard curve, which was expressed as ng/ml for media and ng/)ag 
total proteins for cell lysates. Data represent the mean 土 SD of four 
independent experiments. *: Statistical significant difference compared to 
apoE3 (p<0.05). #: Statistical significant difference compared to apoE2 
(p<0.05). 
Control ApoE2 ApoE3 ApoE4 
Media (ng/ml) 0.00 34.31±2.37* 98.12±4.45 0.71±1.89*# 
Cell Lysates 
0.00 0.40±0.05* 0.72±0.06 0.19±0.09*# 
(ng/ng total proteins) 
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3.2. Cell Morphology Study 
In order to determine whether the three apoE isoforms had different 
effects on inflammation, lipopolysaccharide (LPS) was applied to induce 
the cytokine secretion n macrophage. Upon LPS activation, both the 
control and apoE isoform-expressing cells changed their morphology 
from spherical shape to a more spindle shape (Figure 3.2). Nevertheless, 
no apparent difference was observed among cells expressing different 
apoE isoforms. 
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Figure 3.2 Cellular morphology of control and apoE 
isoform-expressing cells before and after LPS activation. Cells (1 x 10^) 
plated in growth medium overnight were stimulated by LPS (lOOng/ml) 
for 6 hours with one set without LPS activation as control group. The cell 
morphology of control and LPS-activated group were observed under 
light microscope (lOOx magnification). Upon LPS activation, both the 
control and apoE isoform-expressing cells changed their morphology 
from spherical into more spindle shape. 
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3.3. Changes of IL-6 and TNF-a Secretion Associated with Endogenous 
ApoE Isoforms Expression 
3.3.1. In the Presence of Lipoproteins 
The basal secretion of IL-6 and TNF-a were similar among control and 
apoE isoform-expressing cells. (Figures 3.3 and 3.4). Upon LPS 
activation, the secretion of IL-6 and TNF-a in control and 
apoE-isoform-expressinc cells were elevated by 15%-198% and 
l l%-50% respectively, implying that the macrophages were successfully 
activated by LPS to produce these cytokines (Figure 3.3 and 3.4). 
Moreover, upon LPS activation, the IL-6 secretion in apoE2- and 
apoE4-expressing cells was significantly higher than control cells, with an 
increase of 50% and 135%, respectively. In addition, when compared to 
apoE3-expressing cells, apoE2- and apoE4-expressing cells showed a 
significant increase of 48% and 132% in the IL-6 secretion, respectively. 
The IL-6 secretion of apoE4-expressing cells was also significantly higher 
than apoE2-expressing cells by 57% (Figure 3.3). 
Similarly, upon LPS activation, the TNF-a secretion in control, apoE2-
and apoE4-expressifig cells were significantly higher than 
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Figure 3.3 The relative secretion of IL-6 in the control and 
apoE-isoform-expressing cells in the presence of lipoproteins. The 
growth medium contains lipoproteins from the basal group (without LPS 
activation) and the LPS-activated group was collected after 6 hours upon 
the change of growth medium. Equal volumes of media (100|LI1) were 
added into each well of ELISA plates coated with anti-IL-6 antibody. The 
IL-6 level in control cells without apoE expression under basal condition 
was set as one. The IL-6 expression levels of cells in different conditions 
were expressed as fractions of that of control cells. Data represent the 
mean 士 SD of four independent experiments in duplicate set up. The 
secretion of IL-6 was significantly stimulated by LPS in apoE2-, apoE3-
and apoE4-expressing cells as compared to their counterparts at basal 
level (#, j7<0.05). There is no significant difference in the basal secretion 
of IL-6 among control and apoE-isoform expressing cells. Upon LPS 
activation, the secretion of IL-6 is similar between the control and 
apoE3-expressing cells, while apoE2- and apoE4-expressing cells showed 
a significant higher secretion of IL-6 than the control cells p<0.05) and 
apoE3-expressing cells (*，/7<0,05), The secretion level of IL-6 in 
apoE4-expressing cells was also significantly higher than 
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Figure 3.4 The relative secretion of TNF-a in the control and 
apoE-isoform-expressing cells in the presence of lipoproteins. The 
growth medium contains lipoproteins from the basal group (without LPS 
activation) and the LPS-activated group was collected after 6 hours upon 
the change of growth medium. Equal volumes of media (lOOjul) were 
added into each well of ELISA plates coated with anti-TNF-a antibody. 
The TNF-a level in control cells without apoE expression under basal 
condition was set as one. The TNF-a expression levels of cells in 
different conditions were expressed as fractions of that of control cells. 
Data represent the mean 士 SD of six independent experiments in duplicate 
set up. The secretion of TNF-a was significantly stimulated by LPS in 
control, apoE2-, apoE3- and apoE4-expressing cells as compared to their 
counterparts at basal level (#, /KO.05). There is no significant difference 
in the basal secretion of TNF-a among control and apoE-isoform 
expressing cells. Upon LPS activation, apoE3-expressing cells showed the 
strongest suppression on the TNF-a secretion (*, /7<0.05), while apoE2-
and apoE4-expressing cells showed a similar LPS-activated secretion of 
TNF-a than the control cells. 
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3.3.2. Serum/Lipoprotein-independent Effects of ApoE Isoforms 
To investigate whether the isoform-dependent effect of endogenous apoE 
was lipid-dependent, serum free medium without lipoproteins was used in 
the same experiment. Interestingly, the isoform-dependent effect on IL-6 
and TNF-a secretion was similar in the presence and absence of 
lipoproteins. 
The basal secretion of IL-6 and TNF-a were similar among control and 
apoE isoform-expressing cells (Figures 3.5 and 3.6). 
Unlike in the presence of lipoproteins, LPS cannot stimulate the secretion 
of IL-6 and TNF-a in apoE3-expressing cells (Figure 3.5. and 3.6). 
However, the secretion profile of IL-6 and TNF-a in the absence of 
lipoproteins was similar to that of the presence of lipoproteins. Upon LPS 
activation, the IL-6 secretion in apoE2- and apoE4-expressing cells was 
significantly higher than that of the control cells, with an increase of 74% 
and 159%, respectively. In addition, when compared to control, apoE2-
and apoE4-expressing cells, apoE3-expressing cells showed a significant 
suppression of 22%-217% in the IL-6 secretion upon LPS activation. The 
LPS-activated IL-6 secretion in apoE4-expressing cells was also 
significantly higher than apoE2-expressing cells by 49% (Figure 3.5). 
Similarly, upon LPS activation, the TNF-a secretion in apoE3-expressing 
cells was significantly suppressed by 44%-60% when compared to the 
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Figure 3.5 The relative secretion of IL-6 in the control and 
apoE-isoform-expressing cells in the absence of lipoproteins. The 
serum free medium (without lipoproteins) from the basal group (without 
LPS activation) and the LPS-activated group were collected after 6 hours 
upon the change of growth medium. Equal volumes of media (lOOjuil) 
were added into each well of ELISA plates coated with anti-IL-6 antibody. 
The IL-6 level in control cells without apoE expression under basal 
. condition was set as one. The IL-6 expression levels of cells in different 
‘ conditions were expressed as fractions of that of control cells. Data 
represent the mean 士 SD of four independent experiments. The secretion 
of IL-6 was significantly stimulated by LPS in control, apoE2-, and 
apoE4-expressing cells as compared to their counterparts at basal level (#, 
/7<0.05). There is no significant difference in the basal secretion of IL-6 
among control and apoE-isoform expressing cells. Upon LPS activation, 
apoE3-expressing cells suppressed the IL-6 secretion (*，p<0.05), while 
apoE2- and apoE4-expressing cells showed a significant higher 
LPS-activated secretion of IL-6 than the control cells (八，/?<0.05). 
Moreover, the LPS-activated secretion of IL-6 in apoE4-expressing cells 
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Figure 3.6 The relative secretion of TNF-a in the control and 
apoE-isoform-expressing cells in the absence of lipoproteins. The 
serum free medium (without lipoproteins) from the basal group (without 
LPS activation) and the LPS-activated group were collected after 6 hours 
upon the change of growth medium. Equal volumes of media (lOOjiil) 
were added into each well of ELISA plates coated with anti-TNF-a 
antibody. The TNF-a level in control cells without apoE expression under 
basal condition was set as one. The TNF-a expression levels of cells in 
different conditions were expressed as fractions of that of control cells. 
Data represent the mean 土 SD of four independent experiments. The 
secretion of TNF-a was significantly stimulated by LPS in control, 
apoE2-, and apoE4-expressing cells as compared to their counterparts at 
basal level (#, /7<0.05). There is no significant difference in the basal 
secretion of TNF-a among control and apoE-isoform expressing cells. 
Upon LPS activation, apoE3-expressing cells suppressed TNF-a secretion 
(*,/7<0.05). 
65 
3.4. The Effects of Endogenous ApoE Isoform Expression on the Activities 
of MAPK Signaling Pathways 
3.4.1. Study on the Activation Status and Expression of MAPKs 
Since previous studies support the involvement of ERKl/2 and p38 
MAPKs in IL-6 and TNF-a production (Kim et al, 2004, Carter and 
Monick et al., 1999, Brook et ai, 2000), the activation status and the total 
protein expression of individual MAPKs were studied by Western blot. 
1) ERKl/2 MAPK Pathway 
The total protein level of ERKl/2 was similar in the control and apoE 
isoforms-expressing cells (Figure 3.7a). However, the phosphorylated 
form of ERKl/2 was significantly down-regulated in the 
apoE3-expressing cells. As shown in Figure 3.7b, in the basal condition, 
the kinase activities of ERKl/2 in apoE3-expressing cells were 
438%-581%, 284%-420%, and 183%-227% lower than the control, 
apoE2- and apoE4-expressing cells, respectively. While upon LPS 
activation, the kinase activities of ERKl/2 in apoE3-expressing cells were 
469%-577%, 514-545%, 321%-483% lower than the control, apoE2- and 
apoE4-expressing cells, respectively. However, the level of ERKl/2 
phosphorylation upon LPS activation was similar to their counterparts at 
basal condition. The result from our time-point study suggested that the 
phosphorylation of ERKl/2 in apoE3-expressing cells was 
time-dependent but LPS-independent (Figure 3.8). 
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Figure 3.7 Effects of apoE isoforms expression on ERKl/2 MAPKs 
expression and activity. Control and apoE isoform-expressing cells were 
stimulated by lOOng/ml LPS for 6 hours, with one set having the 
replacement of fresh medium containing PBS instead of LPS as basal 
control. Cells were then harvested and equal amounts (50 jug) of protein 
extracts were subjected to immunoblotting. The total protein level of “ 
ERKl/2 and phosphorylated ERKl/2 in control cells without apoE 
expression under basal condition was set as one. The relative expression 
levels of cells in different conditions were expressed as fractions of that of 
the kinase in control cells, a) The total expression of ERKl/2 (a sum of 
phosphorylated and nbn-phosphorylated) in control and 
apoE-isoform-expressing cells before and after LPS activation, b) The 
expression of phosphorylated ERKl/2 in control and 
apoE-isoform-expressing cells before and after LPS activation. Data 
represent the mean ± SD of six independent experiments. The level of 
ERKl/2 phosphorylation upon LPS activation was similar to their 
counterparts at basal condition. ApoE3-expressing cells showed the 
strongest suppression of ERKl/2 phosphorylation in both the basal 
condition (*，p<0.05) and upon LPS activation ( � p < 0 . 0 5 ) , while the 
control, apoE2- and apoE4-expressing cells showed a similar level of 
ERKl/2 phosphorylation in such condition. There is no significant change 
of the total expression of ERKl/2 among the control and 
apoE-isoform-expressing cells, and before and after LPS activation. 
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Figure 3.8 LPS cannot further activate ERKl/2 MAPKs in the 
presence of serum. ApoE3-expressing cells were stimulated by lOOng/ml 
LPS for 1 and 6 hours, with one set having the replacement of fresh 
medium containing PBS instead of LPS as basal control. Cells were then 
harvested and equal amounts (50 |ig) of protein extracts were subjected to 
. immunoblotting. ERKl/2 MAPKs were highly activated after 1 hour upon 
the change of growth medium and the activation decreased after 6 hours. 
The activation level of ERKl/2 MAPKs was similar in the absence or the 
presence of LPS. 
2) p38 MAPK Pathway 
The total protein levels of p38 were similar in the control and apoE 
isoforms-expressing cells (Figure 3.9a). Similar to ERKl/2 MAPKs, the 
phosphorylated form of p38 was significantly down-regulated in the 
apoE3-expressing cells. As shown in Figure 3.9b, in the basal condition, 
the kinase activities of p38 in apoE3-expressing cells were 84%, 161% 
and 75% lower than the control, apoE2- and apoE4-expressing cells, 
respectively. While upoi. LPS activation, the kinase activities of p38 in 
apoE3-expressing cells were 163% and 139% lower than the apoE2- and 
apoE4-expressing cells, respectively. The kinase activities of p38 were 
also significantly higher in apoE2- and apoE4-expressing cells by 103% 
and 84% when compared to control cells upon LPS activation. However, 
there was no significant change in the phosphorylation level of p38 before 
and after LPS activation. The result from our time-point study suggested 
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that the activation of p38 in apoE3-expressing cells was time-dependent 
(Figure 3.10). 
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Figure 3.9 Effects of apoE isoforms expression on p38 MAPK 
expression and activity. Control and apoE isoform-expressing cells were 
stimulated in lOOng/ml LPS for 6 hours, with one set having the 
replacement of fresh medium containing PBS instead of LPS as basal 
control. Cells were then harvested and equal amounts (50 jiig) of protein 
extracts were subjected to immunoblotting. The total protein level of p38 
and phosphorylated p38 in control cells without apoE expression under 
basal condition was set as one. The relative expression levels of cells in 
different conditions were expressed as fractions of that of the kinase in 
control cells, a) The total expression of p38 (a sum of phosphorylated and 
non-phosphorylated) in control and apoE-isoform-expressing cells before 
and after LPS activation. Data represent the mean 土 SD of seven 
independent experiments, b) The expression of phosphorylated p38 in 
control and apoE-isoform-expressing cells before and after LPS activation. 
Data represents the mean 土 SD of six independent experiments. The level 
of p38 phosphorylation upon LPS activation was similar to their 
counterparts at basal condition. ApoE3-expressing cells shoWed the 
strongest suppression of p38 phosphorylation in both the basal condition 
(#，p<0.05) and upon LPS activation (*，p<0.05). Besides, upon LPS 
activation, the level of p38 phosphorylation in apoE2- and 
apoE4-expressing cells was significantly higher than the control cells ( � 
p<0.05). There is no significant change of the total expression of p38 
among the control and apoE-isoform-expressing cells, and before and 
after LPS activation. 
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Figure 3.10 The activation of p38 MAPK by LPS is time-dependent. 
ApoE3-expressing cells were stimulated by lOOng/ml LPS for 1 and 6 
hours, with one set having the replacement of fresh medium containing 
PBS instead of LPS as basal control. Cells were then harvested and equal 
amounts (50 j_ig) of protein extracts were subjected to immunoblotting. 
LPS successfully activates p38 MAPK after 1 hour incubation while the 
activation of p38 MAPK return to its basal level after 6 hour incubation. 
3.4.2. IL-6 and TNF-a Secretion Among ApoE Isoforms in the Presence of 
MEKl/2 Inhibitor 
To investigate the importance of ERKl/2 MAPKs in the 
isoform-dependent secretion of cytokines mediated by endogenous apoE, 
MEKl/2 inhibitor U0126 was applied to specifically block the ERKl/2 
MAPK pathway (Favata et ai, 1998). 
In the absence of MEKl/2 inhibitor, the LPS-activated IL-6 and TNF-a 
secretion in apoE3-expressing cells was significantly lower than those of 
the apoE2- and apoE4-expressing cells by 22%-39% and 13%-18% 
respectively (Figures 3.12 and 3.13). In the presence of MEKl/2 inhibitor, 
the LPS-activated secretion of IL-6 and TNF-a was significantly reduced 
by 15%-32% and 30%-37% respectively when compared to their 
counterparts in the absence of MEKl/2 inhibitor, indicating ERKl/2 
MAPK pathway was important for the LPS-activated IL-6 and TNF-a 
production (Figure 3.12 and 3.13). Moreover, in the presence of MEKl/2 
inhibitor, the difference in LPS-activated IL-6 secretion between apoE2-
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and apoE3-expressing cells and apoE3- and apoE4-expressing cells were 
significantly reduced by 75% and 58%，respectively (Figure 3.12). In 
addition, no significant difference was observed in LPS-activated TNF-a 
secretion among the control and apoE-isoform expressing cells in the 
presence of MEKl/2 inhibitor (Figure 3.13). 
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Figure 3.11 Inhibition of ERKl/2 phosphorylation by U0126. 
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Figure 3.12 The relative secretion of BL-6 in the control and 
apoE-isoform-expressing cells in the presence of MEKl/2 inhibitor 
U0126. The growth medium with lipoproteins from the control group 
(without U0126) and the treatment group (with SOjuM U0126) were 
collected after LPS activation for 6 hours. Equal volumes of medium 
(lOOjLil) were added into each well of ELISA plates coated with anti-IL-6 
antibody. The IL-6 level in control cells without apoE expression before 
the application of MEKl/2 inhibitor was set as one. The IL-6 expression 
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levels of cells in different conditions were expressed as fractions of that of 
control cells. Data represent the mean 土 SD of four experiments in 
duplicate set up. In the absence of MEKl/2 inhibitor, apoE2- and 
apoE4-expressing cells showed a significant higher LPS-activated 
secretion of IL-6 than the control cells p<0.05) and apoE3-expressing 
cells (•, /?<0.05), while the apoE2-expressing cells have a higher 
LPS-activated secretion of IL-6 than the apoE4-expressing cells (@, 
/?<0.05). However, the LPS-activated secretion of IL-6 in 
apoE3-expressing cells is similar to that of the control cells. In the 
presence of MEKl/2 inhibitor, the LPS-activated secretion of IL-6 was 
significantly reduced in the control and apoE-isoform expressing cells 
when compared to their counterparts in the absence of MEKl/2 inhibitor 
(#，/?<0.05). Although a higher LPS-activated secretion of IL-6 in the 
apoE2- and apoE4-expressing cells was still observed when compared to 
the control (八，/7<0.05) and apoE3-expressing cells (*, /?<0.05), the 
differences in LPS-activated IL-6 secretion between apoE2- and 
apoE3-expressing cells and apoE3- and apoE4-expressing cells were 
significantly reduced after the application of MEKl/2 inhibitor (p<0.05). 
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Figure 3.13 The relative secretion of TNF-a in the control and 
apoE-isoform-expressing cells in the presence of MEKl/2 inhibitor 
U0126. The growth medium with lipoproteins from the control group 
(without U0126) and the treatment group (with 50)LIM U0126) were 
collected after LPS activation for 6 hours. Equal volumes of medium 
(1001^1) were added into each well of ELISA plates coated with 
anti-TNF-a antibody. The LPS-activated TNF-a level in control cells 
without apoE expression before the application of MEKl/2 inhibitor was 
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set as one. The TNF-a expression levels of cells in different conditions 
were expressed as fractions of that of control cells. Data represent the 
mean ± SD of four experiments in duplicate set up. In the absence of 
MEKl/2 inhibitor, apoE3-expressing cells showed a lower LPS-activated 
secretion of TNF-a than the control, apoE2- and apoE4-expressing cells 
(*, p<0.05). In the presence of MEKl/2 inhibitor, the LPS-activated 
secretion of TNF-a was significantly reduced in control and apoE-isoform 
expressing cells when compared to their counterparts in the absence of 
MEKl/2 inhibitor (#，p<0.05). Moreover, the LPS-activated secretion of 
TNF-a became similar among the control and apoE-isoform-expressing 
cells after the application of MEKl/2 inhibitor. 
3.4.3. IL-6 and TNF-a Secretion Among ApoE Isoforms in the Presence of 
p38 Inhibitor 
To investigate the importance of p38 MAPKs in the isoform-dependent 
secretion of cytokines mediated by endogenous apoE, p38 inhibitor SB 
203580 was applied to specifically block the p38 MAPK pathway (Lee, J. 
etal., 1999). 
In the absence of p38 inhibitor, the LPS-activated IL-6 secretion in the 
apoE3-expressing cells was significantly lower than the apoE2- and 
apoE4-expressing cells by 49% and 24% respectively (Figures 3.14)， 
while the LPS-activated TNF-a secretion in apoE3-expressing cells was 
significantly lower than apoE2-expressing cells by 26% (Figures 3.15). In 
the presence of p38 inhibitor, the LPS-activated secretion of IL-6 and 
TNF-a was significantly reduced when compared to their counterparts in 
the absence of p38 inhibitor by 5%-29% and 25%-38% respectively, 
indicating p38 MAPK pathway was important in LPS-activated IL-6 and 
TNF-a production (Figure 3.14 and 3.15). Moreover, the 
isoform-dependent secretion of IL-6 and TNF-a were abolised after the 
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application of p38 inhibitor, indicating the importance of p38 MAPK in 
mediating such effects (Figure 3.14 and 3.15). 
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Figure 3.14 The relative secretion of IL-6 in the control and 
apoE-isoform-expressing cells in the presence of p38 inhibitor SB 
203580. The growth medium with lipoproteins from the control group 
(without SB 203580) and the treatment group (with lOjiM SB 203580) 
were collected after LPS activation for 6 hours. Equal volumes of medium 
(100)^1) were added into each well of ELISA plates coated with anti-IL-6 
antibody. The LPS-activated IL-6 level in control cells without apoE 
expression before the application of p38 inhibitor was set as one. The IL-6 
expression levels of cells in different conditions were expressed as 
fractions of that of control cells. Data represent the mean 士 SD of two 
experiments in duplicate set up. In the absence of p38 inhibitor, both 
apoE2- and apoE4-expressing cells showed a significant higher 
LPS-activated secretion of IL-6 than the control cells ( � p < 0 . 0 5 ) and 
apoE3-expressing cells (*，p<0.05), while the apoE2-expressing cells 
even showed a higher LPS-activated secretion of IL-6 than the 
apoE4-expressing cells (@, /><0.05). In the presence of p38 inhibitor, the 
LPS-activated secretion of IL-6 was significantly reduced in the control, 
apoE2- and apoE4-expressing cells (#, p<0.05) when compared to their 
counterparts in the absence of p38 inhibitor. Although the apoE-isoform 
expressing cells still showed a significant higher LPS-activated secretion 
of IL-6 than control cells (八’；7<0,05) in the presence of p38 inhibitor, the 
LPS-activated secretion of IL-6 becomes similar among 
apoE-isoform-expressing cells after the application of p38 inhibitor. 
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Figure 3.15 The relative secretion of TNF-a in the control and 
apoE-isoform-expressing cells in the presence of p38 inhibitor SB 
203580. The growth medium with lipoproteins from the control group 
(without SB 203580) and the treatment group (with 1 0 _ SB 203580) 
were collected after LPS activation for 6 hours. Equal volumes of medium 
(100|al) were added into each well of ELISA plates coated with 
anti-TNF-a antibody. The basal TNF-a level in control cells without apoE 
expression before the application of p38 inhibitor was set as one. The 
TNF-a expression levels of cells in different conditions were expressed as 
fractions of that of control cells. Data represent the mean 士 SD of two 
experiments in duplicate set up. In the absence of p38 inhibitor, the 
LPS-activated secretion of TNF-a in apoE2-expressing cells was 
significantly higher than the control (八，/KO.OS), apoE3- (*, /7<0.05) and 
apoE4-expressing cells (@，/7<0.05). In the presence of p38 inhibitor, the 
LPS-activated secretion of TNF-a was significantly reduced in the control 
and apoE isoform-expressing cells when compared to their counterparts in 
the absence of p38 inhibitor (#, /><0.05). Moreover, the LPS-activated 
secretion of TNF-a becomes similar among the control and 
apoE-isoform-expressing cells after the application of p38 inhibitor. 
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Table 3.2 Summary of the effects of endogenous apoE isoforms on cytokine 
secretion and MAPK activities in macrophages. ApoE3-expresssing cells 
significantly suppressed the LPS-activated secretion of IL-6 and TNF-a in addition 
to the basal and LPS-activated ERKl/2 and p38 phosphorylation. The 
isoform-dependent effects of apoE on cytokine secretions are partially abolished by 
MEKl/2 inhibitor U0126 and completely abolished by p38 inhibitor SB 203580. 
The level of cytokines and MAPK activities in apoE isoform-expressing cells were 
compared to control cells. 
Without LPS With LPS 
Control ApoE2 ApoE3 ApoE4 Control ApoE2 ApoE3 ApoE4 
IL-6 NC NC NC 个 丄* 个个A 
Without 丁 - NC NC NC - - ^ 
inh出itor ^已尺尺丄“； | U ^ ； - 个 山丄* i 
p-p38 - 个 44* vl - 个 NC* 个 
With IL-6 个 NC* t 
蘭 26 TNF-a NC NC NC 
With SB IL-6 - T T T 
203580 TNF-a - NC NC NC 
- ：Baseline control for comparison 
* ： Statistical significant difference compared to apoE3-expressing cells 
NC: No change 
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Chapter 4 ： Discussion 
4.1 Mouse Peritoneal Macrophage Cell Line .I774A.1 as Cell Model 
Since the integration of plasmids into the host cell genome is a random 
process, polyclonal cell lines were used in this study to ensure the changes 
of the inflammatory properties and signal transduction observed was not 
due to clonal variation. Mouse peritoneal macrophage cell line J774A.1 
without native apoE expression has been used in many apoE studies 
(Mabile et al‘, 2003, Mazzone and Reardon et al., 1994，Zhang et al., 
Previous study has shown that the 5114A. 1 cells could successfully 
express transfected human apoE3 cDNA constructs (Ho et al” 2000), 
suggesting that this cell line is capable of hosting the expression of human 
apoE isoforms. Moreover, apoE receptors such as LDL receptor, LRP and 
HSPG are expressed on the surface of J774A.1 cells (Xu et ai, 2001， 
Morita et al., 2004). Thus, extracellular apoE may modulate the cellular 
processes through interaction with apoE receptors. In addition, LPS can 
stimulate the secretion of cytokines, i.e. IL-6 and TNF-a in J774A.1 cells 
(Segura et al., 1999). These properties make the J774A. 1 macrophage cell 
line a suitable model for studying the effects of apoE isoforms on 
inflammation. 
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4.2 Inflammatory Properties Associated with Endogenous ApoE Isoforms 
Expression in Macrophages 
4.2.1 Expression Level of ApoE Isoforms Transgenes in Mouse Peritoneal 
Macrophages 
Previous studies have reported a correlation of apoE genotypes with 
serum apoE protein concentration, with apoE4 carriers showing the 
lowest serum apoE levels (Mahley and Rail, 2000). Interestingly, we 
found that the expression level of apoE4 is lower than apoE2 and apoE3 
in our stable cell lines even with the attempt to obtain cell lines with 
similar apoE protein expression, we still observed a low expression of 
apoE4 in cells from other independent transfections (Ms. Wong Kin-Yee, 
unpublished data). It is speculated that the differences in the expression 
level of apoE isoforms observed in this study represent the physiological 
expression level of apoE in macrophages among carriers of different apoE 
isoforms. 
Although the mechanism behind such low expression level of apoE4 is 
unknown, some possible explanations were suggested. Firstly, the 
turnover rate of apoE4 is more rapid than other apoE isoforms because of 
its preferential association with VLDL which facilitates the cellular 
uptake via receptor-mediated endocytosis (Wahrle and Holtzman et ai, 
2003). Secondly, apoE4 protein has a lower stability and a tendency to 
form folding intermediates (Morrow et ai, 2002). Thirdly, cells might 
recognize apoE4 as misfolded proteins and target them for degradation 
(Ramaswamy et ai, 2005). However, little is known on the expression 
level of apoE2 although previous studies have demonstrated a greater 
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cellular accumulation of apoE3 than apoE2 in neuronal cells, fibroblasts, 
and hepatocytes (Ji et al, 1998). 
4.2.2 Macrophage Activation by LPS 
Incubation of the control and apoE-isoform-expressing macrophages with 
LPS (lOOng/ml) for 6 hours led to a change of cell morphology from 
spherical to spindle shape. This morphological change represents the 
adhesion and spreading of macrophages, which is one of the earliest 
cellular responses to LPS (Schmidt et al, 2001). Moreover, the secretions 
of IL-6 and TNF-a were stimulated by LPS. Both the morphological 
changes and cytokine induction implied that the macrophages were 
successfully activated by LPS treatment in this study. 
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4.2.3 Effect of Endogenous ApoE Isoforms Expression on Cytokine 
Secretion and Signal Transduction in Macrophages 
It is clear that apoE could alter immune response in vivo and in vitro. For 
example, apoE-deficient mice have impaired immunity as they showed 
upregulations of proinflammatory cytokines TNF-a, IL-6, IL-12, and 
IFN-y upon LPS activation (Ali et al., 2005). Moreover, apoE has been 
shown to suppress the activation and proliferation of lymphocytes 
(Bocksch et al., 2001), the generation of cytolytic T-cells, and the 
stimulation of cultured neutrophils in vitro (Laskowitz et al, 2000). 
However, little work has been done to compare the inflammatory 
properties caused by different isoforms in macrophages. 
Our group has previously demonstrated that apoE2- and 
apoE4-expressing cells have significant elevations of IL-6 and TNF-a in 
their mRNA and cell protein level as compared to the apoE3-expressing 
cells upon LPS activation. Similar result was also observed in two sets of 
cell lines with stable expression of apoE isoforms (Ms. Wong Kin-Yee, 
unpublished data). Therefore, for further investigation, one set of cell line 
was used to study the effect of apoE isoform on the secretion of cytokines 
and the underlying mechanism which governed the isoform-dependent 
effect of apoE. 
Since the basal secretion of cytokines in macrophages is close to the 
lowest detection limit, only the effect of endogenous apoE isoform 
expression on LPS-activated secretion of cytokines will be discussed. Our 
results showed that the secretions of IL-6 and TNF-a were the highest in 
LPS-activated apoE4-expressing cells while they were the lowest in 
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LPS-activated apoE3-expressing cells. Combining with our previous 
findings of the mRNA and cellular protein level of IL-6 and TNF-a (Ms. 
Wong Kin-Yee, unpublished data), our results clearly showed that 
endogenous expression of apoE in macrophages could affect the 
transcription, translation and secretion levels of IL-6 and TNF-a in an 
isoform-dependent manner. However, no significant difference was 
observed in the IL-6 and TNF-a secretion when exogenous apoE isoform 
was supplemented (see appendices 5.1.1). Since serum free medium was 
used in the exogenous apoE experiments and apoE is a lipid-associated 
protein, it is unclear at this point whether exogenous apoE can elicit an 
isoform-dependent effect on cytokine secretion in the presence of 
lipoproteins. 
Interestingly, the apoE isoform-dependent secretion of cytokines observed 
in our study is similar to an in vivo study which showed that 
targeted-replacement (TR) mice expressing human AP0E4 gene had a 
significant greater systemic elevation of IL-6 and TNF-a as compared to 
their AP0E3 counterparts upon LPS activation. (Lynch et aL, 2003). The 
increased secretion of both cytokines was also specifically observed in the 
LPS-activated microglia of TR mice expressing human AP0E4 gene 
(Maezawa et al., 2006). However, unlike our study in which apoE3 
showed the most potent anti-inflammatory effect in macrophages, the 
LPS-activated secretion of IL-6 and TNF-a was the lowest in the 
microglia of TR mice expressing human AP0E2 gene (Maezawa et aL, 
2006a). However, the primary astrocytes of TR mice expressing human 
apoE isoform showed a difference in their isoform-dependent secretion of 
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cytokines upon LPS activation, where the primary astrocytes of TR mice 
expressing human AP0E4 gene had the lowest secretion of IL-6 and 
TNF-a while those expressing human AP0E2 gene showed highest 
secretion of both cytokines (Maezawa et al., 2006b). This indicates that 
the apoE isoform-dependent secretion of cytokines may be tissue-specific. 
As elevated levels of IL-6 and TNF-a are associated with increased risks 
of atherosclerosis (Haddy et al, 2003)，possibly through the induction of 
endothelial cell adhesion molecules (Haddy et ai, 2003, Ohta et al., 2005) 
and affecting lipid metabolism (Yudkin et ai, 2000，Mendall and Asante, 
1997，Mendall et al., 1997)，our results suggest that apoE3 is the most 
protective against the disease while apoE4 is the least protective. 
Since ERKl/2 and p38 MAPK have been shown to play important roles 
in LPS-activated IL-6 and TNF-a expression in macrophages (Kim et ai, 
2004，Brook et ai, 2000，Carter et al., 1999)，their activation status in the 
presence of apoE isoforms was determined. Similar to the LPS-activated 
IL-6 and TNF-a secretion, the activation of ERKl/2 and p38 MAPK is 
the lowest in apoE3-expressing cells，and this differential activation of 
MAPKs is not due to the change of the total MAPKs expression and is 
LPS-independent. Although it is known that LPS can activate ERKl/2 and 
p38 MAPK, our results do not support this; the activation level of both 
MAPK was not significantly changed before and after LPS activation. In 
fact, from the results o^ our time-point study, it was shown that both 
MAPKs had been highly activated in our experiments. The activation 
level of ERKl/2 MAPKs was greatly increased after 1 hour upon the 
change of growth medium as compared to its activation level after 6 hours, 
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and this activation was LPS-independent. Since serum contains growth 
factors that can activate ERKl/2 MAPKs, this indicated that serum in the 
growth medium may already activate ERKl/2 MAPKs to a threshold so 
that addition of LPS cannot further increase their activation levels. As for 
p38 MAPK, its activation level was greatly increased after 1 hour upon 
the addition of LPS and restored to its basal activation level after 6 hours. 
Our results support that the isoform-dependent activation of MAPKs is 
LPS-independent since such effects were also observed in the basal 
condition. However, it remains to be substantiated whether the 
LPS-induced activation of ERKl/2 and p38 MAPK is required for 
mediating the isoform-dependent effects of apoE on LPS-activated 
cytokine secretion. 
To prove the differential activation of MAPKs among apoE 
isoform-expressing cells was important for the isoform-dependent effect 
on cytokine secretion, MAPK inhibitor was used to block the MAPK 
activation and the LPS-activated cytokine secretion was monitored. 
Interestingly, when MEKl/2 inhibitor U0126 was applied to specifically 
block the ERKl/2 MAPK pathway, the isoform-dependent effects of apoE 
observed was diminished in IL-6 secretion and even lost in the TNF-a 
secretion. This suggests that ERKl/2 MAPK pathway might play 
important roles in mediating the isoform-dependent effect of apoE on 
cytokine secretion. Since a significant difference remained in the IL-6 
secretion between apoE2- and apoE3-expressing cells and apoE3- and 
apoE4-expressing cells after the application of MEKl/2 inhibitor, the 
ERKl/2 MAPK pathway only partially explain the isoform-dependent 
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effects of apoE on IL-6 secretion. Since our results also showed an apoE 
isoform-dependent activation of p38 MAPK, the p38 MAPK might be 
another possible pathway involved in mediating the apoE 
isoform-dependent secretion of cytokines upon LPS activation. To prove 
this, p38 MAPK inhibitor SB 203580 was applied and our result showed 
that the isoform-dependent secretion of IL-6 and TNF-a was completely 
abolished after the application of p38 inhibitor. This suggests p38 MAPK 
is important in mediating the isoform-dependent secretion of cytokines in 
addition to ERKl/2 MAPK. 
Since the apoE isoform-^.ependent secretion of cytokines is only observed 
upon LPS activation, suggesting these MAPKs interact with other 
LPS-activated signaling pathway to mediate such isoform-dependent 
effect. One of the possible candidates is the I K B - N F - K B pathway as it is 
always activated by LPS in addition to MAPKs (Guha and Mackman, 
2001) and N F - K B is an important transcription factor in regulating the 
macrophage expression of IL-6 and TNF-a (Dendorfer, 1996; Zagariya et 
al,，1998). Further experiment is required to confirm the role of 
I K B - N F - K B pathway on the apoE isoform-dependent cytokine secretions, 
for example we can block the I K B - N F - K B pathway by specific inhibitors 
to see how the apoE isoform-dependent cytokine secretions is affected. 
Since the differential activation of MAPKs among apoE 
isoform-expressing cells was also observed in the basal condition, the 
endogenous expression of apoE isoforms might lead to changes of other 
cellular functions as the ERKl/2 and p38 MAPKs also play other 
important roles in cells in addition to regulating cytokine secretion. For 
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example, in relation to atherosclerosis, the activation of the ERKl/2 is 
required for the expression of matrix metalloproteinase (an enzyme that 
degrades connective tissues) (Lai et al, 2003) while the activation of p38 
MAPK is required for f(�am cell formation (Zhao et al, 2002). Since the 
activations of ERKl/2 and p38 MAPK were always suppressed in 
apoE3-expressing cells in the present study, it implies that the expression 
of apoE3 might lead to other phenotypes that are unfavorable for the 
development of atherosclerosis. 
In addition, it is of interest to know whether the isoform-dependent effect 
on cytokine secretion mediated by endogenous apoE isoforms involves 
the LDL receptor-mediated signaling mechanism. Researches have shown 
that only lipidated apoE can bind to LDL receptor (Saito et al, 2001, 
Fisher et al., 2000), yet, our result showed that the isoform-dependent 
effect of apoE on cytokine secretion was still observed in the absence of 
serum lipoproteins. Hence, it is speculated that such effect is independent 
of the LDL receptor-mediated signaling mechanisms. Nevertheless, 
delipidated apoE can interact with LRP (Narita et al, 2002) and cell 
surface HSPG (Weisgraber et al, 1986) to affect cell signaling. Moreover, 
as previous studies have reported that the intracellular apoE is mainly 
localized to the Goigi compartments of macrophages (Ho et al., 2000)，it 
is possible that the immunoregulatory effect observed in endogenous 
apoE isoform expression is due to the interaction between apoE and 
cytoplasmic MAPKs. 
In this study, the expression levels of endogenous apoE isoforms were 
significantly different. Since some cell functions such as the binding to 
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beta-amyloid (LaDu et ai, 1994) and suppression of glial secretion of 
TNF-a (Laskowitz et ai, 1997) are dependent on the dosage of apoE, it is 
possible that the lowest secretion of cytokine and the suppression of 
MAPKs observed in apoE3-expressing cells might be due to its highest 
expression level among the three isoforms. However, a recent study has 
reported that an apoE isoform-dependent anti-proliferative effect could be 
observed even at an apoE dosage of �5-fo ld lower than our study (Chan et 
al., 2006). Therefore, it is still unclear whether the isoform-dependent 
effect of apoE on inflammatory properties of macrophages observed in 
this study is due to the different expression level of endogenous apoE 
isoforms. Further experiment is required to confirm the apoE 
isoform-mediated effects. 
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Figure 4.1 An overview of the signaling mechanisms mediating the 
apoE isoform-dependent secretion of cytokines. LPS activates 
signaling pathways to induce IL-6 and TNF-a secretion. ERKl/2 and p38 
MAPK interact with these signaling pathways to affect cytokine secretion 
based on their activity. Since apoE2, apoE3 and apoE4 have differential 
effects on the activity of ERKl/2 and p38 MAPKs upon LPS activation, 
in which apoE2 and apoE4 have a higher activation of the ERKl/2 and 
p38 MAPKs than apoE3, this result in an apoE isoform-dependent 
cytokine secretion. In the presence of the MEKl/2 inhibitor U0126, the 
apoE isoform-dependent secretion of TNF-a was lost, while such effect 
on IL-6 secretion was partially abolished. In the presence of the p38 
inhibitor SB 203580, the apoE isoform-dependent secretion of both IL-6 
and TNF-a were completely abolished, showing both ERKl/2 and p38 
MAPK contributed to the apoE isoform-dependent secretion of cytokines. 
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4.3 Conclusions and Future Prospects 
4.3.1 Conclusions 
1) Endogenously expressed apoE affects secretion of cytokines in 
macrophages in an isoform-dependent manner, with apoE3 being the 
most potent inhibitor of LPS-activated IL-6 and TNF-a secretion 
among apoE isoforms. This effect is independent of 
serum/lipoproteins. 
2) Endogenously expressed apoE suppress ERKl/2 and p38 MAPKs in 
an isoform-dependent manner, with apoE3 being the most potent 
isoform in suppressing these MAPKs. This effect is 
LPS-independent. 
3) The ERKl/2 MAPK pathway partially mediates the apoE 
isoform-dependent secretion of cytokines whereas p38 MAPK 
completely mediates such effect. 
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4.3.2 Future Prospects 
Monoclonal cell lines with equal expression of apoE can be applied to 
address the dosage effect of apoE among isoforms. N F - K B inhibitor can 
be applied to study the importance of LPS-activated I K B - N F - K B pathway 
in the apoE isoform-dependent cytokine secretion. 
Previous study has suggested apoE may play a role in the regulation of 
arachidonic acid metabolism (Langer et al., 2000). Since arachidonic acid 
can alter cell function by activating MAPK (Bianchi et ai, 2002, Talukdar 
et al” 2005) and the level of arachidonic acid affects the secretion of IL-6 
and TNF-a in macrophage (Holladay et ai, 1993, Hubbard et al” 1993), 
it is interesting to know whether the isoform-dependent secretion of 
cytokine is due to a differential regulation of arachidonic acid metabolism 
in the presence of different apoE isoforms. The level of arachidonic acid 
and its metabolites in the three apoE-isoform expressing macrophages can 
be studied by gas chromatography. 
The isoform-dependent effect on macrophage cytokine secretion and 
activation of MAPKs in the presence of exogenous and endogenous apoE 
may provide clues to explain why the inheritance of 83 alleles is 
associated with a protection against atherosclerosis while the s4 alleles is 
associated with an increased risk to the disease. 
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Chapter 5 ： Appendices 
5.1. Changes of Inflammatory Properties of Macrophages Supplemented 
with Exogenous ApoE Isoforms 
5.1.1. Changes of IL-6 and TNF-a Secretion in Macrophages Supplemented 
with Exogenous ApoE Isoforms 
Both the LPS-activated secretion of IL-6 and TNF-a were significantly 
higher than their basal level by 8%-28% and 21%-48%, respectively 
(Figure 5.1 and 5.2). The basal secretion of IL-6 was significantly 
lowered in apoE-isoform-expressing cells by 13%-16% when compared 
to the control cells. There was no significant difference in the IL-6 
secretion among control and apoE-isoforms-expressing cells after LPS 
activation (Figure 5.1). 
However, in the absence of LPS, the secretion of TNF-a in 
apoE-isoform-expressing cells was slightly higher than control cells by 
3%-19%. Interestingly, "'n the presence of LPS, the secretion of TNF-a 
was slightly suppressed in apoE-isoform-expressing cells by 3%-9% 
when compared to control cells (Figure 5.2). 
There was no significant difference in the IL-6 and TNF-a secretion 
among apoE-isoform-expressing cells before and after LPS activation 
(Figure 5.1 and 5.2). 
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Figure 5.1 The relative secretion of IL-6 in the presence of 
exogenous apoE isoforms. The medium from the basal group (without 
LPS activation) and the LPS-activated group were collected after 6 hours 
upon the change of serum free medium (without lipoproteins). Equal 
volumes of medium (lOOjiil) were added into each well of ELISA plates 
coated with anti-IL-6 antibody. The basal IL-6 level in control cells 
without apoE expression was set as one. The IL-6 expression levels of 
cells in different conditions were expressed as fractions of that of control 
cells. Data represent the mean 士 SD of three independent experiments in 
quadruplicate set up. The secretion of IL-6 was significantly increased in 
control, apoE2, apoE3 and apoE4-expressing cells stimulated by LPS (#, 
/7<0.05). ApoE2-, apoE3- and apoE4-expressing cells showed a 
significant reduced secretion of IL-6 as compared to the control cells in 
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Figure 5.2 The relative secretion of TNF-a in the presence of 
exogenous apoE isoforms. The medium from the basal group (without 
LPS activation) and the LPS-activated group were collected after 6 hours 
upon the change of serum free medium without lipoproteins. Equal 
volumes of medium (100|il) were added into each well of ELISA plates 
coated with anti-TNF-a antibody. The basal TNF-a level in control cells 
without apoE expression was set as one. The TNF-a expression levels of 
cells in different conditions were expressed as fractions of that of control 
cells. Data represent the mean 士 SD of three independent experiments in 
quadruplicate set up. The secretion of TNF-a was significantly increased 
in control, apoE2, apoE3 and apoE4-expressing cells compared to their 
basal level counter parts (#, pxO.OS). ApoE2-, apoE3- and 
apoE4-expressing cells showed a significant increased secretion of TNF-a 
as compared to the control cells in the absence of LPS (@,p<0.05)，while 
the basal secretion level of TNF-a was the highest in apoE3-expressing 
cells (*, /?<0.05). In the presence of LPS, they showed a significant 
reduction of TNF-a secretion compared to the control cells (^,p<0.05). 
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5.1.2. Changes of Signal Transduction in Macrophages Supplemented with 
Exogenous ApoE Isoforms 
5.1.2.1. Study on the Activation Status and Expression of MAPKs 
1) ERKl/2 MAPK Pathway 
The total protein and phosphorylated level of ERKl/2 was similar in the 
control and among exogenous apoE isoforms, without and upon LPS 
activation (Figure 5.3a and 5.3b). The phosphorylation of ERKl/2 before 
LPS activation was not shown due to the inconsistency of results. 
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Figure 5.3 Effects of exogenous apoE isoforms on ERKl/2 MAPKs 
expression and activity. Exogenous apoE isoforms (5 |Lig/ml) were added 
in both the basal control and LPS-treated group. Cells in the LPS-treated 
groups were stimulated by lOOng/ml LPS for 6 hours, while those in the 
basal group having the replacement of fresh medium containing PBS 
instead of LPS. Cells were then harvested and equal amounts (50 ing) of 
protein extracts were subjected to immunoblotting. a) The total expression 
of ERKl/2 (a sum of phosphorylated and non-phosphorylated) in the 
presence of exogenous apoE isoforms before and after LPS activation. 
The total protein level of ERKl/2 in control cells without exogenous apoE 
expression before LPS activation was set as one. The ERKl/2 expression 
levels of cells in different conditions were expressed as fractions of that of 
control cells, b) The expression of phosphorylated ERKl/2 in the 
presence of exogenous apoE isoforms after LPS activation. The protein 
level of phosphorylated ERKl/2 in control cells without exogenous apoE 
expression after LPS activation was set as one. The phosphorylated 
ERKl/2 expression levels of cells in different conditions were expressed 
as fractions of that of control cells. Data represent the mean 士 SD of three 
independent experiments. There is no significant change of the total 
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expression and phosphorylation of ERKl/2 MAPKs among exogenous 
apoE isoforms. 
2) p38 MAPK Pathway 
The total protein and phosphorylated level of p38 was similar in the 
control and among exogenous apoE isoforms, without and upon LPS 
activation (Figure 5.4a and 5.4b). The phosphorylation of p38 before LPS 
activation was not shown due to the inconsistency of results. 
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Figure 5.4 Effects of exogenous apoE isoforms on p38 MAPK 
expression and activity. Exogenous apoE isoforms (5 jiig/ml) were added 
in both the basal control and LPS-treated group. Cells in the LPS-treated 
groups were stimulated in lOOng/ml LPS for 6 hours, while those in the 
basal group having the replacement of fresh medium containing PBS 
instead of LPS. Cells were then harvested and equal amounts (50 |Lig) of 
protein extracts were subjected to immunoblotting. a) The total expression 
of p38 (a sum of phosphorylated and non-phosphorylated) in the presence 
of exogenous apoE isoforms before and after LPS activation. The total 
protein level of p38 in control cells without exogenous apoE expression 
before LPS activation was set as one. The p38 expression levels of cells in 
different conditions were expressed as fractions of that of control cells, b) 
The expression of phosphorylated p38 in the presence of exogenous apoE 
isoforms after LPS activation. The protein level of phosphorylated p38 in 
control cells without exogenous apoE expression after LPS activation was 
set as one. The phosphorylated p38 expression levels of cells in different 
conditions were expressed as fractions of that of control cells. Data 
represent the mean 士 SD of three independent experiments. There is no 
significant change of the total expression and phosphorylation of p38 
among exogenous apoE isoforms. 
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